

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Patient characteristics and disease burden of alopecia areata in the Danish Skin Cohort (DSC)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-053137
Article Type:	Cohort profile
Date Submitted by the Author:	06-May-2021
Complete List of Authors:	Andersen, Yuki M F; University of Copenhagen, Department of Dermatology and Allergy Nymand, Lea; University of Copenhagen, Department of Dermatology DeLozier, Amy M.; Eli Lilly and Company Burge, Russel T.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, United States , Global Health Outcomes Edson-Heredia, E.; Eli Lilly Egeberg, A; Bispebjerg Hospital, Department of Dermatology
Keywords:	DERMATOLOGY, Dermatological epidemiology < DERMATOLOGY, Dermatology < INTERNAL MEDICINE

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

**Title Page****Title**

Cohort profile: patient characteristics and disease burden of alopecia areata in the Danish Skin Cohort (DSC)

**Manuscript word, table and figure count**

2,604 words, 3 tables, 0 figures

**Authors full names, departments, and institutions**

Yuki M F Andersen<sup>1</sup> MD, PhD; Lea K Nymand<sup>2</sup> MSc; Amy M. DeLozier<sup>3</sup> MPH; Russel Burge<sup>3,4</sup> PhD;

Emily Edson-Heredia<sup>3</sup> MPH; Alexander Egeberg<sup>2</sup> MD, PhD

- 1) Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
- 2) Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark
- 3) Eli Lilly and Company, Indianapolis, Indiana, United States
- 4) Division of Pharmaceutical Sciences, University of Cincinnati, Cincinnati, OH, United States

**Corresponding author**

Yuki Andersen, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Kildegårdsvej 28, 2900 Hellerup, Denmark

Telephone: (0045) 38673157

E-mail: yuki.maria.fukuda.andersen.01@regionh.dk

## Abstract (299/300)

### Purpose

Alopecia areata (AA) is a common disorder of patchy hair loss which carries a substantial psychological burden for patients. The current understanding of AA prevalence, disease course and burden is limited, and further research is needed to improve patient care. This prospective cohort of AA patients within the Danish Skin Cohort was established to provide data that can serve as a tool in future AA research.

### Participants

A total of 1494 patients with dermatologist verified AA were included in the cohort. Patients were invited and included through electronic or phone-based questionnaires. Information regarding demographics, biometrics, lifestyle factors, skin type, AA onset and development, health related quality of life, and self-reported severity assessment was collected.

### Findings to date

The mean (SD) age of AA onset was 32.7 (17.6) years. The mean body mass index and history of cigarette smoking was comparable with the general population and slightly lower than for patients with psoriasis. The majority (92.5%) of participants were Caucasian. In total, 72.4% of patients received their diagnosis by a physician within a year after onset of symptoms, and 66.9% reported to still have symptoms of AA within the past year. A total of 12% reported to have a first-degree family member with AA. 31.4% of patients were missing all or nearly all hairs on their scalp, 32.2% had no or barely no eyelashes and 36.2% had no or barely no eyebrow hairs. Overall, most patients (55.7%) did not experience irritated eyes, but 30% reported slight eye irritation, and 47.2% reported no damage to finger- or toenails.

### Future plans

1  
2  
3  
4 Observational studies regarding comorbidities, psychosocial burden of AA and efficacy of pharmacological  
5 interventions will be carried out, and additional data will be linked from nationwide registries of routinely  
6 collected data. Furthermore, follow-up survey data will be added for longitudinal analyses.  
7  
8  
9

### 10 11 12 13 **Strengths and limitations of this study** 14

- 15  
16 • The AA cohort within the Danish Skin Cohort is comprises a very number adults  
17 with AA that were interviewed by trained professionals.  
18  
19
- 20 • AA diagnoses are established by dermatologists for all patients.  
21  
22
- 23 • Patients were not informed of the topic and contents of the projects until they  
24 agreed to participate, thereby reducing participation bias.  
25  
26  
27
- 28 • Collected information includes validated patient reported outcome measures  
29 specifically developed for AA.  
30  
31  
32  
33
- 34 • Future linkage to Danish national health registries enables us to follow patients for a  
35 prolonged period of time.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 Limitations include risk of recall bias as the cohort is based on patient interviews.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Alopecia areata (AA) is a common hair loss disorder with a life-time prevalence estimated to be approximately 2% in the US.[1,2] The condition affects both children and adults and typically presents as well-demarcated patches of hair loss in the scalp without significant visible inflammation or scarring. AA may progress to involve the entire scalp (alopecia totalis) or all scalp and body hairs (alopecia universalis).[3] The course of AA is unpredictable, and regrowth and relapse may occur, alternately. The condition is furthermore associated with atopic predispositions and various autoimmune diseases, in particular thyroid disease and vitiligo.[4] The exact pathophysiology of AA is unknown, however it is considered to be a T-cell mediated autoimmune condition where hair follicles enter the telogen phase (resting phase) prematurely, resulting in hair loss.[5,6]

Although AA is a common condition in dermatological practice, understanding of prevalence, prognosis, and impact on patients' lives remain scarce and the condition is understudied compared with some other inflammatory skin diseases. A detailed description of patients with AA and establishment of a prospective cohort will enable better understanding of AA and secure an increased recognition within the field of dermatological research. Furthermore, a well-described patient cohort may serve as a tool in future research and assessment of efficacy of future emerging therapies. The aim of the current paper was to present the establishment of a new AA cohort within the Danish Skin Cohort and to describe patient demographics and characteristics.

## COHORT DESCRIPTION

This study was a population-based cross-sectional study using data from the extended Danish Skin Cohort. Information regarding patient characteristics, disease onset, severity and patient-reported outcomes were collected using questionnaires or structured interviews.

## **The Danish Skin Cohort**

The Danish Skin Cohort was established in 2018 to study the prevalence, morphology, and burden of skin diseases in Denmark.[7] The cohort originally consisted of three independent samples. Sample A representing a random sample of general population adults in Denmark. Sample B and C representing groups of patients with a dermatologist verified plaque psoriasis, and atopic dermatitis, respectively. All participants in this prospective cohort were adults ( $\geq 18$  years) at the time of inclusion. In 2020, the Danish Skin Cohort was extended to also include patients with AA, hidradenitis suppurativa, and rosacea. Patients with AA were identified using the Danish National Patient Registry. The registry contains information on all hospital contacts (both in- and outpatient) in Denmark, as well as a number of private practice dermatology clinics. Each visit is coded with a diagnostic code based on the International Classification of Diseases (ICD) system.[8] All patients with an ICD-10 code for AA recorded in the Danish National Patient Registry at least once during adulthood (i.e. after their 18<sup>th</sup> birthday) were identified and invited to participate in the cohort. Participants were not informed that the research project was related to skin diseases until they had agreed to participate and were simply informed that the research was “regarding people in the Danish population”. This was to reduce the risk of participation bias. Study individuals had the opportunity to withdraw from participation upon accepting the invitation, and throughout the study. A total of 3198 adults with a diagnosis of AA were invited to participate.

## **Patient and Public Involvement**

Patients were not involved in the development of the research questions or outcome measures, but all responses to these interviews were provided by AA patients.

## **Patient interviews**

All communications from the government and official institutions in Denmark are sent to citizens to a personal and secure digital mailbox. Citizens are notified through a text message or email and they are obliged to check the mailbox on a regular basis. Individuals who were eligible to participate in the Danish



1  
2  
3  
4 Skin Cohort received an invitation to participate and were interviewed through a digital questionnaire. In  
5  
6 case of non-response, individuals were sent a reminder after one week, and were contacted by phone or mail  
7  
8 up to a total of five times. In case of a phone interview, participants were interviewed in a structured manner  
9  
10 by professional researchers.

11  
12 Information on patient demographics including age at participation, sex, height in cm, weight in kg, smoking  
13  
14 history and quantity, current alcohol consumption, level of physical activity, and Fitzpatrick skin type (range  
15  
16 1 to 5) was obtained. Other variables included age of AA onset, time from onset to diagnosis by physician,  
17  
18 time from onset to dermatologist referral, AA symptoms and activity during the past 12 months, family  
19  
20 history of AA, episodes of flares or worsening in AA symptoms during the past 12 months, seasonal  
21  
22 variation in symptoms, and the affected hair loss in percentages. Current self-perceived severity of AA  
23  
24 symptoms was recorded using a numeric rating scale (NRS) from 0 to 10, where 10 represents the highest  
25  
26 degree of severity. Additional patient-reported outcomes included Dermatology Life Quality Index (DLQI),  
27  
28 Work Productivity and Activity Index (WPAI), EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L), and the  
29  
30 Multidimensional Fatigue Inventory-20 (MFI-20). Additional patient reported outcome (PRO) measures  
31  
32 included assessment of nail appearance, eye irritation, affection of eye lashes, involvement of eyebrows, and  
33  
34 scalp hair assessment.[9] A full list of the obtained information is available from **Supplementary Table 1**.  
35  
36  
37  
38  
39  
40  
41

## 42 **Statistical analysis**

43  
44 Characteristics of patients with AA were presented using summary statistics. Continuous variables with a  
45  
46 normal distribution were presented as means and standard deviations (SD), while medians and interquartile  
47  
48 ranges (IQR) were presented for non-normal continuous variables. Categorical variables were presented as  
49  
50 frequencies and percentages. As the data were purely descriptive no test for significance was carried out.  
51  
52  
53

## 54 **Patient demographics**

55  
56  
57  
58  
59  
60

1  
2  
3  
4 A total of 1494 patients with AA accepted the invitation and were included. The mean age (SD) at inclusion  
5 was 51.3 (16.0) years, with a strong female predominance of 67% (**Table 1**). The mean age (SD) at AA onset  
6 was 32.7 (17.6) years (**Table 2**). Previous epidemiological studies have shown contradicting results  
7  
8 regarding the gender distribution among AA patients, where some studies show an equal distribution, while  
9  
10 others show a greater representation of either sexes.[1,2,10] The gender distribution may vary according to  
11  
12 study population and study design. Our observation may partially reflect a higher awareness of hair loss  
13  
14 among women. Furthermore, the skewed distribution may represent different response rates in different  
15  
16 demographic groups, where middle aged women tend to have higher response rates than young men, for  
17  
18 example. The reported age of AA onset in our cohort is similar to previous reports, where the majority of  
19  
20 patients tend to experience first onset of AA before the age of 40. A literature review has estimated that the  
21  
22 mean age of onset of AA is between 25.2 and 36.3 years.[2] Hair loss in children, adolescents and young  
23  
24 adults often has a big impact on the patients' self-esteem, and therefore less likely to be affected by recall  
25  
26 bias.[11]  
27  
28  
29  
30  
31  
32  
33  
34  
35

## 36 FINDINGS TO DATE

### 37 38 39 **Body mass index and lifestyle factors**

40  
41 The mean (SD) BMI in the AA population was 25.8 (5.2). According to World Health Organization  
42  
43 classification of BMI, 2.3% were classified as underweight, 47.2% as normal weight, 34.9% as overweight  
44  
45 10.8% as obese and 4.8% as morbidly obese. Almost half of the patients had never smoked (47.1%), while  
46  
47 34.0% and 19.0% were former and current smokers, respectively. Furthermore, 54.7% rated themselves to  
48  
49 having a moderate physical activity level, while 24.3% and 1.3% reported a vigorous and athletic physical  
50  
51 activity level, respectively. Lastly, 19.7% reported a sedentary lifestyle.  
52  
53  
54

55 In comparison, patients from the Danish Skin Cohort with psoriasis have a slightly higher mean (SD) BMI of  
56  
57 27.5 (6.5), while patients with atopic dermatitis have a similar mean (SD) BMI of 25.9 (5.6) (data on  
58  
59  
60

1  
2  
3  
4 file).[12] The prevalence of cigarette smoking in patients with AA was comparable with the general  
5  
6 population and lower than in patients with psoriasis in the Danish Skin Cohort.[12] The psychological stress  
7  
8 of having AA may influence patients' smoking habits, however the low mean age at onset could explain why  
9  
10 AA patients resemble the general population. Traditionally, AA is not considered a disease associated with  
11  
12 obesity and lifestyle related risk factors like e.g. patients with psoriasis. The current evidence on the  
13  
14 cardiovascular risk in patients with AA is limited and studies show conflicting results.[13–15] Cigarette  
15  
16 smoking was found to be associated with an increased risk of AA in a recent cohort study from Taiwan,  
17  
18 however further studies are needed to establish a relationship.[16]  
19  
20  
21  
22  
23  
24

### 25 **Fitzpatrick skin type**

26  
27 We found that the majority (92.5%) of patients with AA in our cohort reported a Fitzpatrick skin type 1, 2 or  
28  
29 3. Only 6.5% and 1.0%, respectively reported a skin type 4 and 5. To our knowledge, no data on skin type  
30  
31 distribution is published on the Danish general population, therefore we lack a comparison group for this  
32  
33 outcome.  
34  
35  
36

37 Racial disparities seem to exist in the prevalence of AA, and recent US epidemiologic studies have reported  
38  
39 that African Americans have a higher odds of AA, while Asians have a lower odds of AA compared with  
40  
41 Caucasians.[17,18] Furthermore, differences in disease prevalence according to geographical location and  
42  
43 ethnicity is well described in autoimmune diseases such as lupus erythematosus, rheumatoid arthritis and  
44  
45 multiple sclerosis.[19,20] The Danish population is considered to be primarily Caucasian, thus not  
46  
47 representative for investigating this characteristic of AA.  
48  
49  
50  
51  
52

### 53 **Dermatology Life Quality Index**

54  
55 Patients with AA in our cohort reported a mean (SD) DLQI of 2.1 (3.7) and median (IQR) DLQI of 1 (0-2).  
56  
57 DLQI is a broadly used and validated outcome to measure the impact of dermatological diseases on patients'  
58  
59  
60

1  
2  
3  
4 quality of life. The score ranges from 0 to 30, where a high score signifies a high impact on health-related  
5 quality of life. We found a remarkably low DLQI in our AA cohort. One reason could be that while patients  
6 with active progressive disease may be highly affected, patients with a steady state may be less affected by  
7 AA at the time of the questionnaire. Furthermore, the DLQI system is not designed specifically for AA, and  
8 therefore some of the questions e.g., regarding itch, pain and physical activities are not suitable for assessing  
9 the impact of AA. Arguably, DLQI is an inappropriate measure to thoroughly assess quality of life related to  
10 AA, since it predominantly refers to cutaneous symptoms rather than symptoms associated with hair loss.

11  
12  
13  
14  
15  
16  
17  
18  
19  
20 Although AA is neither life-threatening nor necessarily accompanied by physical pain, the condition may  
21 have a significant impact on patients' quality of life. A systematic review and meta-analysis summarized that  
22 the mean pooled DLQI score of patients with AA in three studies was 6.3 (95% CI 5.6-7.1).[21]

23  
24  
25  
26 Interestingly, a dose-response relationship between severity of AA and health related quality of life is  
27 uncertain,[21] possibly indicating that a small patch of hair loss may be just as impactful as a larger area of  
28 hair loss. Patients with AA may carry a significant psychological burden due to the visible loss of hair and  
29 the unpredictable disease course, which in turn may cause symptoms such as anxiety, depression, stress, and  
30 sleep deprivation.[22,23] Hair loss may also carry a stigma relating to other forms of illnesses and oncologic  
31 chemotherapy.

### 32 33 34 35 36 37 38 39 **AA-specific patient reported outcomes**

40  
41  
42 PROs related specifically to AA included information about eye irritation, missing eyelashes, missing  
43 eyebrows, damaged nails and missing scalp hair. Overall, most patients in our cohort did not experience  
44 irritated eyes (55.7%), however nearly 30% reported slight eye irritation, 10.3% and 4.8% had moderate and  
45 severe eye irritation, respectively (**Table 3**). Most patients either reported having full eyelashes (43.6%) or  
46 no/barely no eyelashes (32.2%) on each eyelid, and full eyebrows (37.3%) or no/barely no eyebrow hairs  
47 (36.2%). When rating the finger- or toenails most patients (47.2%) answered that the nails were not at all  
48 damaged (**Table 3**). Notably however, most people (31.4%) were missing nearly all or all scalp hair (95-  
49 100% of the scalp is missing hair), suggesting that a high proportion of patients had severe scalp disease.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## AA diagnosis

The mean (SD) time from onset of symptoms to diagnosis at a general practitioner (GP) was 1.0 (3.4) years (**Table 2**). The majority of patients (72.4%) reported that less than a year had passed from the first symptoms of AA until a diagnosis by the GP, while 17.9% and 9.7% reported more than one- and two-years delay, respectively. More than half of the patients (66.9%) reported that they had symptoms of AA within the past 12 months. The mean (SD) current self-reported degree of AA was 7.4 (3.2) and the median (IQR) was 9 (5-10) on a numeric rating scale from 0-10.

General practitioners in Denmark are not trained in using methods such as trichoscopy, and to prevent misclassification of individuals with other forms of hair-loss, all patients included in our cohort had to be diagnosed with AA by a dermatologist. The relatively short time interval from onset of symptoms to contact with a GP indicates an urgency and need for diagnosis and intervention for patients with AA. Interestingly, the self-reported degree of AA was rather high (median 9), while on the other hand 46.9% of the patients reported that they were only missing 0 to 20% of scalp hair. This observation suggests that the subjective burden of AA may not directly correlate with objective measures.

## Family history of AA

When asked about history of AA in the family, approximately 5% reported that either a sibling or a parent had been diagnosed with AA. Furthermore, 4% and 3% reported that a grandparent or child had AA. A total of 179 patients (12%) had at least one first degree family member with AA. An increased incidence of AA in first-degree family members have previously been reported in up to 42% of patients. Furthermore, observational studies, twin studies and genome-wide association studies suggests a strong genetic component in pathogenesis of AA, similar to other autoimmune diseases.[24,25] The family history of AA may be underestimated in our cohort, as the condition is considered medically benign and patients with mild and/or transient symptoms may not have discussed it with their family members.

## STRENGTHS AND LIMITATIONS

The AA extension in the Danish Skin Cohort represents a large group of patients with AA and provides an opportunity to investigate a range of variables and patient reported outcomes longitudinally. The data may also be linked with routinely collected healthcare data from the nationwide Danish registries and gives us a unique opportunity to combine information on clinical manifestations of AA with pharmacological, socio-demographic data, as well as possible comorbidity data. As with all questionnaire-based studies, this cohort carries a risk of recall bias, however the majority of patients had symptoms within the past 12 months of participation, increasing the chance of a more accurate recollection. We expect a low risk of misclassification of patients, as all participants have been diagnosed by a dermatologist. We sought to reduce the risk of participation bias by not informing about the content of the project before accepting to participate, however it is likely that some demographic groups are better represented than others, resulting in a skewed gender and/or age distribution. The overall response rate was 46.7%, which is in the normal range for surveys in Denmark. The DLQI data must be interpreted with caution, as the questionnaire is designed for one week recall period and some questions are more suitable for other skin conditions such as psoriasis rather than AA. Furthermore, data concerning Fitzpatrick skin type may not be extrapolated to countries with other ethnic compositions.

## COLLABORATION

The AA cohort was established to bring new insight in disease characteristics as well as the impact of AA on different aspects of life including social, occupational and psychological behaviour. By adding longitudinal follow-up data, we hope to describe the disease trajectory and prognosis of AA, as well as explore the burden of disease over time. Furthermore, by adding routinely collected data we will be able to investigate comorbidities and efficacy of pharmacological interventions. A deepened and more holistic understanding of

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

AA will hopefully increase awareness of the disorder and facilitate personalized treatment strategies. Future collaboration projects with other research groups are of interest, especially collaborations where study results may be replicated in other cohorts internationally.

For peer review only

### Contributor statement

Dr. Egeberg had full access to all of data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. *Study concept and design:* Egeberg. *Acquisition, analysis, and interpretation of data:* All authors. *Drafting of the manuscript:* Andersen and Egeberg. *Critical revision of the manuscript for important intellectual content:* All authors. *Statistical analysis:* Egeberg. *Obtained funding:* Egeberg. *Administrative, technical, or material support:* All authors. *Study supervision:* All authors.

### Competing interests

Dr. Andersen has received research funding from Kgl Hofbundtmager Aage Bang Foundation and AP Moller Foundation. Ms. Nymand has nothing to declare. Dr. Burge, Mrs. Delozier and Mrs. Edson-Heredia are employees and stockholders of Eli Lilly and Company. Dr. Egeberg has received research funding from Pfizer, Eli Lilly, Novartis, Bristol-Myers Squibb, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Galápagos NV, Sun Pharmaceuticals, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, and Janssen Pharmaceuticals.

### Funding

Development of this manuscript was supported by Eli Lilly and Company.

### Study approvals

The project was approved by the Danish Data Protection Agency, and registered at the Capital Region's inventory (VD-2018-286).

### Data sharing statements



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

There are no plans on sharing the raw data, however, data from the Danish Skin Cohort will be available for research collaborations upon obtaining the necessary legal approvals.

For peer review only

## References

- 1 Mirzoyev SA, Schrum AG, Davis MDP, *et al.* Lifetime incidence risk of alopecia areata estimated at 2.1% by rochester epidemiology project, 1990-2009. *J. Invest. Dermatol.* 2014;**134**:1141–2. doi:10.1038/jid.2013.464
- 2 Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: A systematic review. *Clin. Cosmet. Investig. Dermatol.* 2015;**8**:397–403. doi:10.2147/CCID.S53985
- 3 Gilhar A, Etzioni A, Paus R. Alopecia Areata. *N Engl J Med* 2012;**366**:1515–25. doi:10.1056/NEJMra1103442
- 4 Chu SY, Chen YJ, Tseng WC, *et al.* Comorbidity profiles among patients with alopecia areata: The importance of onset age, a nationwide population-based study. *J Am Acad Dermatol* 2011;**65**:949–56. doi:10.1016/j.jaad.2010.08.032
- 5 Strazzulla LC, Wang EHC, Avila L, *et al.* Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis. *J Am Acad Dermatol* 2018;**78**:1–12. doi:10.1016/j.jaad.2017.04.1141
- 6 Islam N, Leung PSC, Huntley AC, *et al.* The autoimmune basis of alopecia areata: A comprehensive review. *Autoimmun Rev* 2015;**14**:81–9. doi:10.1016/j.autrev.2014.10.014
- 7 Egeberg A, Andersen YMF, Thyssen JP. Prevalence and characteristics of psoriasis in Denmark: Findings from the Danish skin cohort. *BMJ Open* 2019;**9**:e028116. doi:10.1136/bmjopen-2018-028116
- 8 Schmidt M, Schmidt SAJ, Sandegaard JL, *et al.* The Danish National Patient Registry: a review of content, data quality, and research potential. *Clin Epidemiol* 2015;**7**:449–90. doi:10.2147/CLEP.S91125

- 1  
2  
3  
4 9 Wyrwich KW, Kitchen H, Knight S, *et al.* Development of the Scalp Hair Assessment  
5 PRO™ measure for alopecia areata. *Br J Dermatol* 2020;**183**:1065–72.  
6  
7  
8  
9 doi:10.1111/bjd.19024  
10  
11 10 Kyriakis K, Paltatzidou K, Kosma E, *et al.* Alopecia areata prevalence by gender and age. *J*  
12 *Eur Acad Dermatology Venereol* 2009;**23**:572–3. doi:10.1111/j.1468-3083.2008.02956.x  
13  
14  
15 11 Aşkın Ö, Koyuncu Z, Serdaroğlu S. Association of alopecia with self-esteem in children and  
16 adolescents. *Int J Adolesc Med Health* 2020;**1**. doi:10.1515/ijamh-2020-0100  
17  
18  
19  
20 12 Egeberg A, Griffiths CEM, Williams HC, *et al.* Clinical characteristics, symptoms and  
21 burden of psoriasis and atopic dermatitis in adults. *Br J Dermatol* 2020;**183**:128–38.  
22  
23  
24  
25  
26  
27 13 Gwillim EC, Jimenez J, Ali Y, *et al.* 205 Risk of ischemic heart disease in patients with  
28 alopecia areata: A large, urban, retrospective Midwestern US patient population study. *J*  
29 *Invest Dermatol* 2019;**139**:S35. doi:10.1016/j.jid.2019.03.281  
30  
31  
32  
33  
34 14 Huang KP, Joyce CJ, Topaz M, *et al.* Cardiovascular risk in patients with alopecia areata  
35 (AA): A propensity-matched retrospective analysis. *J Am Acad Dermatol* 2016;**75**:151–4.  
36  
37  
38  
39  
40  
41 15 Kang JH, Lin HC, Kao S, *et al.* Alopecia areata increases the risk of stroke: A 3-year follow-  
42 up study. *Sci Rep* 2015;**5**:1–6. doi:10.1038/srep11718  
43  
44  
45  
46 16 Dai YX, Yeh FY, Shen YJ, *et al.* Cigarette Smoking, Alcohol Consumption, and Risk of  
47 Alopecia Areata: A Population-Based Cohort Study in Taiwan. *Am J Clin Dermatol*  
48 2020;**21**:901–11. doi:10.1007/s40257-020-00547-7  
49  
50  
51  
52 17 Lee H, Jung SJ, Patel AB, *et al.* Racial characteristics of alopecia areata in the United States.  
53 *J Am Acad Dermatol* 2020;**83**:1064–70. doi:10.1016/j.jaad.2019.06.1300  
54  
55  
56  
57 18 Thompson JM, Park MK, Qureshi AA, *et al.* Race and Alopecia Areata amongst US Women.  
58  
59  
60

- 1  
2  
3  
4 *J Investig Dermatology Symp Proc* 2018;**19**:S47–50. doi:10.1016/j.jisp.2017.10.007
- 5  
6  
7 19 Roberts MH, Erdei E. Comparative United States autoimmune disease rates for 2010–2016  
8 by sex, geographic region, and race. *Autoimmun Rev* 2020;**19**:102423.  
9  
10 doi:10.1016/j.autrev.2019.102423
- 11  
12  
13 20 Moroni L, Bianchi I, Lleo A. Geoepidemiology, gender and autoimmune disease. *Autoimmun*  
14 *Rev* 2012;**11**:A386–92. doi:10.1016/j.autrev.2011.11.012
- 15  
16  
17 21 Rencz F, Gulácsi L, Péntek M, *et al.* Alopecia areata and health-related quality of life: a  
18 systematic review and meta-analysis. *Br J Dermatol* 2016;**175**:561–71.  
19  
20  
21 doi:10.1111/bjd.14497
- 22  
23  
24 22 Okhovat J-P, Marks DH, Manatis-Lornell A, *et al.* Association Between Alopecia Areata,  
25 Anxiety, and Depression: A Systematic Review and Meta-analysis. *J Am Acad Dermatol*  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- 23 Dai YX, Tai YH, Chen CC, *et al.* Bidirectional association between alopecia areata and sleep  
disorders: a population-based cohort study in Taiwan. *Sleep Med* 2020;**75**:112–6.  
doi:10.1016/j.sleep.2020.06.015
- 24 Biran R, Zlotogorski A, Ramot Y. The genetics of alopecia areata: New approaches, new  
findings, new treatments. *J Dermatol Sci* 2015;**78**:11–20. doi:10.1016/j.jdermsci.2015.01.004
- 25 Petukhova L, Duvic M, Hordinsky M, *et al.* Genome-wide association study in alopecia  
areata implicates both innate and adaptive immunity. *Nature* 2010;**466**:113–7.  
doi:10.1038/nature09114

Table 1 – Patient characteristics

	Alopecia Areata n=1494
<b>Age at inclusion, mean (SD)</b>	51.3 (16.0)
<b>Sex, n (%)</b>	
Female	1003 (67.1)
Male	491 (32.9)
<b>BMI, n (%)</b>	
<18.5	34 (2.3)
18.5 – 25	705 (47.2)
>25 – 30	522 (34.9)
>30 - 35	161 (10.8)
>35	72 (4.8)
<b>BMI, Mean (SD)</b>	25.8 (5.2)
<b>Smoking status, n (%)</b>	
Current daily smoker	205 (13.7)
Current occasional smoker	78 (5.2)
Former smoker	508 (34.0)
Never smoker	703 (47.1)
<b>Physical activity, n (%)</b>	
sedentary	294 (19.7)
moderate	814 (54.7)
vigorous	362 (24.3)
athletic	19 (1.3)
<b>Fitzpatrick skin type, n (%)</b>	
1	106 (7.1)
2	605 (40.5)
3	671 (44.9)
4	97 (6.5)
5	15 (1.0)
<b>DLQI, n (%)</b>	
0-2	1128 (75.5)
3-5	220 (14.7)
6-9	83 (5.6)
10-14	36 (2.4)
15-19	13 (0.9)
≥20	14 (0.9)
<b>DLQI, median (IQR)</b>	1 (0 - 2)

BMI, Body Mass Index; DLQI, Dermatology Life Quality Index;  
IQR, interquartile range; SD, standard deviation

**Table 2 – History of Alopecia Areata**

	<b>Alopecia Areata n=1494</b>
<b>Age at AA onset, mean (SD)</b>	32.72 (17.6)
<b>Years from onset of symptoms to diagnosis by a general practitioner</b>	
Mean (SD)	0.99 (3.4)
Less than one year, n (%)	105 (72.4)
One year, n (%)	26 (17.9)
Two or more years, n (%)	14 (9.7)
<b>Years from onset of symptoms to diagnosis by a dermatologist</b>	
Mean (SD)	1.18 (4.5)
Less than one year, n (%)	671 (68.5)
One year, n (%)	198 (20.2)
Two or more years, n (%)	110 (11.2)
<b>Did you have AA within the last 12 months? n (%)</b>	
Yes	741 (66.9)
<b>Patient reported current severity of AA, NRS 0-10</b>	
Mean (SD)	7.37 (3.2)
Median (IQR)	9 (5-1)
<b>Family history of AA, n (%)</b>	
Siblings	56 (5.1)
Mother	47 (4.2)
Father	59 (5.3)
Grand parents	43 (3.9)
Children	32 (2.9)
At least one 1. degree family with AA	179 (12.0)

AA, Alopecia Areata; IQR, interquartile range; NRS, Numeric rating scale; SD, standard deviation

**Table 3 – AA-specific patient reported outcomes**

	Alopecia Areata n=1494
<b>[PRO Measure for Eye Irritation] Please rate how irritated (e.g. itching, stinging, burning, or dry) either of your eyes have been in the past 7 days, n(%)</b>	
My eyes have not been irritated	828 (55.65)
My eyes have been a little irritated	436 (29.30)
My eyes have been moderately irritated	153 (10.28)
My eyes have been severely irritated	71 (4.77)
<b>[PRO Measure for Eyelashes] Look at your upper and lower eyelashes on both your eyes. Please rate your eyelashes, as they look today, n(%)</b>	
I have full eyelashes on each eyelid	481 (43.61)
I have a minimal gap or minimal gaps along the eyelids	203 (18.40)
I have a large gap or large gaps along the eyelids	64 (5.80)
I have no or barely any eyelash hair	355 (32.18)
<b>[PRO Measure for Eyebrows] Look at the hair in both of your eyebrows. Please rate your eyebrows, as they look today, n(%)</b>	
I have full eyebrows on each eye	412 (37.25)
I have a minimal gap(s) or a minimal amount of thinning in at least one of my eyebrows	180 (16.27)
I have a large gap(s) or a large amount of thinning in at least one of my eyebrows	114 (10.31)
I have no or barely any eyebrow hairs	400 (36.17)
<b>[PRO Measure for Nail Appearance] Examine your fingernails and toenails. Please rate your fingernails and toenails, as they look today, n(%)</b>	
Nails are not at all damaged (e.g. pitted, rough, brittle, split)	522 (47.24)
At least one nail is a little damaged (e.g. pitted, rough, brittle, split)	303 (27.42)
At least one nail is moderately damaged (e.g. pitted, rough, brittle, split)	193 (17.47)
At least one nail is very damaged (e.g. pitted, rough, brittle, split) or you have lost at least one nail	87 (7.87)
<b>[Scalp Hair Assessment PRO] Use mirrors to look at your entire scalp. Please rate the total area of your scalp that is missing hair right now, n(%)</b>	
No missing hair (0% of my scalp is missing hair; I have a full head of hair)	234 (21.16)
A limited area (1-20% of my scalp is missing hair)	284 (25.68)
A moderate area (21-49% of my scalp is missing hair)	132 (11.93)
A large area (50-94% of my scalp is missing hair)	109 (9.86)
Nearly all or all (95-100% of my scalp is missing hair)	347 (31.37)
PRO, patient reported outcome;	

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



## Supplementary table 1

## List of variables available from the baseline assessment interviews in the Danish Skin Cohort

Variable	Type	Choice	Details
Height	Continuous	Single	Centimetres
Weight	Continuous	Single	Kilograms
Smoking	Categorical	Single	Current daily smoker Current non-daily smoker Former smoker Never smoker
Alcohol use	Continuous	Single	Units of alcohol per week
Alcohol use	Categorical	Single	AUDIT-C for alcohol, questionnaire (multiple questions, one variable for each question)
Skin type	Categorical	Single	Fitzpatrick skin types 0-6
Leisure time activity level	Ordinal	Single	Athletic Vigorous Moderate Sedentary
Joint pain within last 7 days	Interval	Single	Numeric Rating Scale (0 to 10)
Skin pain within last 7 days	Interval	Single	Numeric Rating Scale (0 to 10)

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46	Skin pruritus within last 3 days	Interval	Single	Numeric Rating Scale (0 to 10)
	Trouble sleeping within last 3 days	Interval	Single	Numeric Rating Scale (0 to 10)
	Age at AA onset	Continuous	Single	Age in years
	Active AA in the past 12 months	Dichotomous	Single	Yes / No
	Family history of AA	Categorical	Multiple	Sibling Mother Father Grandparent Children
	Current body surface area affected by AA at any point during the past 12 months affected by AA	Interval	Single	0 to 100
	Largest body surface area affected by AA at any point during the past 12 months	Interval	Single	0 to 100
	Largest body surface area affected by AA at any point during the past 12 months affected by AA at any point in your life	Interval	Single	0 to 100
	Patient reported current disease severity	Interval	Single	Numeric Rating Scale (0 to 10)
	Disease development/progression in the past 12 months	Categorical	Single	AA has worsened a lot AA has worsened AA has remained unchanged AA has improved a little AA has improved a lot AA has gone into complete remission

Number of disease flares in the past 12 months	Continuous	Single	A flare is defined as one or more consecutive days with significant worsening of symptoms requiring escalation of treatment or seeking additional medical advice
Time from first AA symptoms to first AA diagnosis by a physician	Continuous	Single	Time in years
Time from first AA symptoms to first AA diagnosis by a dermatologist	Continuous	Single	Time in years
Seasonal changes in severity	Categorical	Multiple	Worsens during spring Worsens during summer Worsens during fall Worsens during winter No seasonal variation
WPAI			Work productivity and activity index Multiple variables (one for each question)
EQ-5D-5L			EuroQoL 5 Dimensions 5 Levels Multiple variables (one for each question)
DLQI			Dermatology Life Quality Index Multiple variables (one for each question)
MFI-20			Multidimensional Fatigue Inventory Multiple variables (one for each question)
AASIS			Alopecia Areata Symptom Impact Scale Multiple variables (one for each question)
PRO Measure for Eye Irritation	Ordinal	Single	Please rate how irritated (e.g. itching, stinging, burning, or dry) either of your eyes have been in the past 7 days.

			<p>My eyes have not been irritated</p> <p>My eyes have been a little irritated</p> <p>My eyes have been moderately irritated</p> <p>My eyes have been severely irritated</p>
PRO Measure for Eyebrows	Ordinal	Single	<p>Look at the hair in both of your eyebrows. Please rate your eyebrows, as they look today. This question asks about gap(s) in your eyebrows or thinning in your eyebrows. If you have gap(s) in your eyebrows and thinning in your eyebrows, please choose your answer based on the type of hair loss that bothers you the most.</p> <p>I have full eyebrows on each eye</p> <p>I have a minimal gap(s) or a minimal amount of thinning in at least one of my eyebrows</p> <p>I have a large gap(s) or a large amount of thinning in at least one of my eyebrows</p> <p>I have no or barely any eyebrow hairs</p>
PRO Measure for Eyelashes	Ordinal	Single	<p>Look at your upper and lower eyelashes on both your eyes. Please rate your eyelashes, as they look today.</p> <p>I have full eyelashes on each eyelid</p> <p>I have a minimal gap or minimal gaps along the eyelids</p> <p>I have a large gap or large gaps along the eyelids</p> <p>I have no or barely any eyelash hair</p>
PRO Measure for Nail Appearance	Ordinal	Single	<p>Examine your fingernails and toenails. Please rate your fingernails and toenails, as they look today.</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

			<p>Nails are not at all damaged (e.g. pitted, rough, brittle, split)</p> <p>At least one nail is a little damaged (e.g. pitted, rough, brittle, split)</p> <p>At least one nail is moderately damaged (e.g. pitted, rough, brittle, split)</p> <p>At least one nail is very damaged (e.g. pitted, rough, brittle, split) or you have lost at least one nail</p>
Scalp Hair Assessment PRO	Ordinal	Single	<p>Use mirrors to look at your entire scalp.</p> <p>Please rate the total area of your scalp that is missing hair right now.</p> <p>Areas of vellus hair (peach fuzz or baby hair) should also be considered as missing hair.</p> <p>No missing hair (0% of my scalp is missing hair; I have a full head of hair)</p> <p>A limited area (1-20% of my scalp is missing hair)</p> <p>A moderate area (21-49% of my scalp is missing hair)</p> <p>A large area (50-94% of my scalp is missing hair)</p> <p>Nearly all or all (95-100% of my scalp is missing hair)</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7
Bias	9	Describe any efforts to address potential sources of bias	NA
Study size	10	Explain how the study size was arrived at	7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Table
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6-7
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	NA
		(d) If applicable, describe analytical methods taking account of sampling strategy	Na
		(e) Describe any sensitivity analyses	Na
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	7
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8-11
		(b) Indicate number of participants with missing data for each variable of interest	
Outcome data	15*	Report numbers of outcome events or summary measures	8-11
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	8-11

		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	11-12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12
Generalisability	21	Discuss the generalisability (external validity) of the study results	12
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	None

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Cohort profile: Patient characteristics and disease burden of alopecia areata in the Danish Skin Cohort (DSC)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-053137.R1
Article Type:	Cohort profile
Date Submitted by the Author:	25-Nov-2021
Complete List of Authors:	Andersen, Yuki M F; University of Copenhagen, Department of Dermatology and Allergy Nymand, Lea; University of Copenhagen, Department of Dermatology DeLozier, Amy M.; Eli Lilly and Company Burge, Russel T.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, United States , Global Health Outcomes Edson-Heredia, E.; Eli Lilly Egeberg, A; Bispebjerg Hospital, Department of Dermatology
<b>Primary Subject Heading</b>:	Dermatology
Secondary Subject Heading:	Epidemiology
Keywords:	DERMATOLOGY, Dermatological epidemiology < DERMATOLOGY, Dermatology < INTERNAL MEDICINE

SCHOLARONE™  
Manuscripts





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

**Title Page****Title**

Cohort profile: Patient characteristics and disease burden of alopecia areata in the Danish Skin Cohort (DSC)

**Manuscript word, table and figure count**

2,604 words, 3 tables, 0 figures

**Authors full names, departments, and institutions**

Yuki M F Andersen<sup>1</sup> MD, PhD; Lea K Nymand<sup>2</sup> MSc; Amy M. DeLozier<sup>3</sup> MPH; Russel Burge<sup>3,4</sup> PhD;  
Emily Edson-Heredia<sup>3</sup> MPH; Alexander Egeberg<sup>2</sup> MD, PhD

- 1) Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
- 2) Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark
- 3) Eli Lilly and Company, Indianapolis, Indiana, United States
- 4) Division of Pharmaceutical Sciences, University of Cincinnati, Cincinnati, OH, United States

**Corresponding author**

Yuki Andersen, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Kildegårdsvej 28,  
2900 Hellerup, Denmark

Telephone: (0045) 38673157

E-mail: [yuki.maria.fukuda.andersen.01@regionh.dk](mailto:yuki.maria.fukuda.andersen.01@regionh.dk)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **Abstract (299/300)**

### **Purpose**

Alopecia areata (AA) is a common disorder of patchy hair loss which carries a substantial psychological burden for patients. The current understanding of AA prevalence, disease course and burden is limited, and further research is needed to improve patient care. This prospective cohort of AA patients within the Danish Skin Cohort was established to provide data that can serve as a tool in future studies of e.g., AA epidemiology and disease burden.

### **Participants**

A total of 1494 patients with dermatologist-verified AA were included in the cohort. Patients were invited and included through electronic or phone-based questionnaires. Information regarding demographics, biometrics, lifestyle factors, skin type, AA onset and development, health related quality of life, and self-reported severity assessment was collected.

### **Findings to date**

The mean (SD) age of AA onset was 32.7 (17.6) years. The mean body mass index and history of cigarette smoking was comparable with the general population. The majority (92.5%) of participants were Caucasian. In total, 72.4% of patients received their diagnosis by a physician within a year after onset of symptoms, and 66.9% reported to still have symptoms of AA within the past year. A total of 12% reported to have a first-degree family member with AA. In total, 31.4% of patients were missing all or nearly all hairs on their scalp, 32.2% had no or barely no eyelashes and 36.2% had no or barely no eyebrow hairs. Overall, most patients (55.7%) did not experience irritated eyes, but 30% reported slight eye irritation, and 47.2% reported no damage to finger- or toenails.

### **Future plans**

1  
2  
3  
4 Observational studies regarding comorbidities, psychosocial burden of AA and efficacy of pharmacological  
5 interventions will be carried out, and additional data will be linked from nationwide registries of routinely  
6 collected data. Furthermore, follow-up survey data will be added for longitudinal analyses.  
7  
8  
9

### 10 11 12 13 **Strengths and limitations of this study** 14

- 15  
16 • The AA cohort within the Danish Skin Cohort comprises a very large number adults with  
17  
18 AA that were interviewed by trained professionals.  
19
- 20  
21 • AA diagnoses are verified by dermatologists for all patients.  
22
- 23  
24 • Patients were not informed of the topic and contents of the projects until they agreed to  
25  
26 participate, thereby reducing participation bias.  
27  
28
- 29  
30 • Collected information includes validated patient reported outcome measures specifically  
31  
32 developed for AA.  
33  
34
- 35  
36 • Future linkage to Danish national health registries enables us to follow patients for a  
37  
38 prolonged period of time.  
39  
40  
41  
42  
43  
44

45  
46 Limitations include risk of recall bias as the cohort is based on patient interviews.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Alopecia areata (AA) is a common hair loss disorder with a life-time prevalence estimated to be approximately 2% in the US.[1,2] The condition affects both children and adults and typically presents as well-demarcated patches of hair loss in the scalp without significant visible inflammation or scarring. AA may progress to involve the entire scalp (alopecia totalis) or all scalp and body hairs (alopecia universalis).[3] The course of AA is unpredictable, and regrowth and relapse may occur, alternately. The condition is furthermore associated with atopic predispositions and various autoimmune diseases, in particular thyroid disease and vitiligo.[4] The exact pathophysiology of AA is unknown, however it is considered to be a T-cell mediated autoimmune condition where hair follicles enter the telogen phase (resting phase) prematurely, resulting in hair loss.[5,6]

Although AA is a common condition in dermatological practice, understanding of prevalence, prognosis, and impact on patients' lives remain scarce and the condition is understudied compared with inflammatory skin diseases such as atopic dermatitis and psoriasis. A detailed description of patients with AA and establishment of a prospective cohort will enable better understanding of AA and secure an increased recognition within the field of dermatological research. Furthermore, a well-described patient cohort may serve as a tool in future research and assessment of efficacy of future emerging therapies. The aim of the current paper was to present the establishment of a new AA cohort within the Danish Skin Cohort and to describe patient demographics and characteristics.

## COHORT DESCRIPTION

This study was a population-based cross-sectional study using data from the extended Danish Skin Cohort. Information regarding patient characteristics, disease onset, severity and patient-reported outcomes were collected using questionnaires or structured interviews.

## The Danish Skin Cohort

The Danish Skin Cohort was established in 2018 to study the prevalence, morphology, and burden of skin diseases in Denmark.[7] The cohort originally consisted of three independent samples. Sample A representing a random sample of general population adults in Denmark. Sample B and C representing groups of patients with a dermatologist verified plaque psoriasis, and atopic dermatitis, respectively. All participants in this prospective cohort were adults ( $\geq 18$  years) at the time of inclusion. In 2020, the Danish Skin Cohort was expanded to also include patients with AA, hidradenitis suppurativa, and rosacea. Patients with AA were identified using the Danish National Patient Registry. The registry contains information on all hospital contacts (both in- and outpatient) in Denmark, as well as a number of private practice dermatology clinics. Each visit is coded with a diagnostic code based on the International Classification of Diseases (ICD) system.[8] All patients with an ICD-10 code for AA recorded in the Danish National Patient Registry at least once during adulthood (i.e. after their 18<sup>th</sup> birthday) were identified and invited to participate in the cohort. Participants were not informed that the research project was related to skin diseases until they had agreed to participate and were simply informed that the research was “regarding people in the Danish population”. This was to reduce the risk of participation bias. Study individuals had the opportunity to withdraw from participation upon accepting the invitation, and throughout the study. A total of 3198 adults with a diagnosis of AA were invited to participate.

## Ethical approval

Review of an ethics committee is not required in Denmark for studies not involving human tissue.

## Patient and Public Involvement

Patients were not involved in the development of the research questions or outcome measures, but all responses to these interviews were provided by AA patients.

## Patient interviews

1  
2  
3  
4 All communications from the government and official institutions in Denmark are sent to citizens to a  
5 personal and secure digital mailbox. Citizens are notified through a text message or email and they are  
6 obliged to check the mailbox on a regular basis. Individuals who were eligible to participate in the Danish  
7 Skin Cohort received an invitation to participate and were interviewed through a digital questionnaire. In  
8 case of non-response, individuals were sent a reminder after one week, and were contacted by phone or mail  
9 up to a total of five times. In case of a phone interview, participants were interviewed in a structured manner  
10 by professional researchers.

11 Information on patient demographics including age at participation, sex, height in cm, weight in kg, smoking  
12 history and quantity, current alcohol consumption, level of physical activity, and Fitzpatrick skin type (range  
13 1 to 5) was obtained. Other variables included age of AA onset, time from onset to diagnosis by physician,  
14 time from onset to dermatologist referral, AA symptoms and activity during the past 12 months, family  
15 history of AA, episodes of flares or worsening in AA symptoms during the past 12 months, seasonal  
16 variation in symptoms, and the affected hair loss in percentages. Current self-perceived severity of AA  
17 symptoms was recorded using a numeric rating scale (NRS) from 0 to 10, where 10 represents the highest  
18 degree of severity. Additional patient-reported outcomes included Dermatology Life Quality Index (DLQI),  
19 Work Productivity and Activity Index (WPAI), EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L), and the  
20 Multidimensional Fatigue Inventory-20 (MFI-20). Additional patient reported outcome (PRO) measures  
21 included assessment of nail appearance, eye irritation, affection of eye lashes, involvement of eyebrows, and  
22 scalp hair assessment.[9] A full list of the obtained information is available from **Supplementary Table 1**.

### 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 **Statistical analysis**

49 Characteristics of patients with AA were presented using summary statistics. Continuous variables with a  
50 normal distribution were presented as means and standard deviations (SD), while medians and interquartile  
51 ranges (IQR) were presented for non-normal continuous variables. Categorical variables were presented as  
52 frequencies and percentages. As the data were purely descriptive no test for significance was carried out.

## Patient demographics

A total of 1494 patients with AA accepted the invitation and were included. The mean age (SD) at inclusion was 51.3 (16.0) years, with a strong female predominance of 67% (**Table 1**). The mean age (SD) at AA onset was 32.7 (17.6) years (**Table 2**). Previous epidemiological studies have shown contradicting results regarding the gender distribution among AA patients, where some studies show an equal distribution, while others show a greater representation of either sexes.[1,2,10] The gender distribution may vary according to study population and study design. Our observation may partially reflect a higher awareness of hair loss among women. Furthermore, the skewed distribution may represent different response rates in different demographic groups, where middle aged women tend to have higher response rates than young men, for example. The reported age of AA onset in our cohort is similar to previous reports, where the majority of patients tend to experience first onset of AA before the age of 40. A literature review has estimated that the mean age of onset of AA is between 25.2 and 36.3 years.[2] Hair loss in children, adolescents and young adults often has a big impact on the patients' self-esteem, and therefore less likely to be affected by recall bias.[11]

## FINDINGS TO DATE

### Body mass index and lifestyle factors

The mean (SD) BMI in the AA population was 25.8 (5.2). According to World Health Organization classification of BMI, 2.3% were classified as underweight, 47.2% as normal weight, 34.9% as overweight 10.8% as obese and 4.8% as morbidly obese. Almost half of the patients had never smoked (47.1%), while 34.0% and 19.0% were former and current smokers, respectively. Furthermore, 54.7% rated themselves to having a moderate physical activity level, while 24.3% and 1.3% reported a vigorous and athletic physical activity level, respectively. Lastly, 19.7% reported a sedentary lifestyle.



1  
2  
3  
4 In comparison, patients from the Danish Skin Cohort with psoriasis have a slightly higher mean (SD) BMI of  
5  
6 27.5 (6.5), while patients with atopic dermatitis have a similar mean (SD) BMI of 25.9 (5.6) (data on  
7  
8 file).[12] The prevalence of cigarette smoking in patients with AA was comparable with the general  
9  
10 population and lower than in patients with psoriasis in the Danish Skin Cohort.[12] The psychological stress  
11  
12 of having AA may influence patients' smoking habits, however the low mean age at onset could explain why  
13  
14 AA patients resemble the general population. Traditionally, AA is not considered a disease associated with  
15  
16 obesity and lifestyle related risk factors like e.g., patients with psoriasis. The current evidence on the  
17  
18 cardiovascular risk in patients with AA is limited and studies show conflicting results.[13–15] Cigarette  
19  
20 smoking was found to be associated with an increased risk of AA in a recent cohort study from Taiwan,  
21  
22 however further studies are needed to establish a relationship.[16]  
23  
24  
25  
26  
27  
28

### 29 **Fitzpatrick skin type**

30  
31  
32 We found that the majority (92.5%) of patients with AA in our cohort reported a Fitzpatrick skin type 1, 2 or  
33  
34 3. Only 6.5% and 1.0%, respectively reported a skin type 4 and 5. To our knowledge, no data on skin type  
35  
36 distribution is published on the Danish general population, therefore we lack a comparison group for this  
37  
38 outcome.  
39

40  
41 Racial disparities seem to exist in the prevalence of AA, and recent US epidemiologic studies have reported  
42  
43 that African Americans have a higher odds of AA, while Asians have a lower odds of AA compared with  
44  
45 Caucasians.[17,18] Furthermore, differences in disease prevalence according to geographical location and  
46  
47 ethnicity is well described in autoimmune diseases such as lupus erythematosus, rheumatoid arthritis and  
48  
49 multiple sclerosis.[19,20] The Danish population is considered to be primarily Caucasian, thus not  
50  
51 representative for investigating this characteristic of AA.  
52  
53  
54  
55  
56

### 57 **Dermatology Life Quality Index**

1  
2  
3  
4 Patients with AA in our cohort reported a mean (SD) DLQI of 2.1 (3.7) and median (IQR) DLQI of 1 (0-2).  
5  
6 DLQI is a broadly used and validated outcome to measure the impact of dermatological diseases on patients'  
7  
8 quality of life. The score ranges from 0 to 30, where a high score signifies a high impact on health-related  
9  
10 quality of life. We found a remarkably low DLQI in our AA cohort. One reason could be that while patients  
11  
12 with active progressive disease may be highly affected, patients with a steady state may be less affected by  
13  
14 AA at the time of the questionnaire. Furthermore, the DLQI system is not designed specifically for AA, and  
15  
16 therefore some of the questions e.g., regarding itch, pain and physical activities are not suitable for assessing  
17  
18 the impact of AA. Arguably, DLQI is an inappropriate measure to thoroughly assess quality of life related to  
19  
20 AA, since it predominantly refers to cutaneous symptoms rather than symptoms associated with hair loss.  
21  
22

23  
24 Although AA is neither life-threatening nor necessarily accompanied by physical pain, the condition may  
25  
26 have a significant impact on patients' quality of life. A systematic review and meta-analysis summarized that  
27  
28 the mean pooled DLQI score of patients with AA in three studies was 6.3 (95% CI 5.6-7.1).[21]  
29

30 Interestingly, a dose-response relationship between severity of AA and health related quality of life is  
31  
32 uncertain,[21] possibly indicating that a small patch of hair loss may be just as impactful as a larger area of  
33  
34 hair loss. Patients with AA may carry a significant psychological burden due to the visible loss of hair and  
35  
36 the unpredictable disease course, which in turn may cause symptoms such as anxiety, depression, stress, and  
37  
38 sleep deprivation.[22,23] Hair loss may also carry a stigma relating to other forms of illnesses and oncologic  
39  
40 chemotherapy.  
41  
42

#### 43 **AA-specific patient reported outcomes**

44  
45  
46 PROs related specifically to AA included information about eye irritation, missing eyelashes, missing  
47  
48 eyebrows, damaged nails and missing scalp hair. Overall, most patients in our cohort did not experience  
49  
50 irritated eyes (55.7%), however nearly 30% reported slight eye irritation, 10.3% and 4.8% had moderate and  
51  
52 severe eye irritation, respectively (**Table 3**). Most patients either reported having full eyelashes (43.6%) or  
53  
54 no/barely no eyelashes (32.2%) on each eyelid, and full eyebrows (37.3%) or no/barely no eyebrow hairs  
55  
56 (36.2%). When rating the finger- or toenails most patients (47.2%) answered that the nails were not at all  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

damaged (**Table 3**). Notably however, most people (31.4%) were missing nearly all or all scalp hair (95-100% of the scalp is missing hair), suggesting that a high proportion of patients had severe scalp disease.

### **AA diagnosis**

The mean (SD) time from onset of symptoms to diagnosis at a general practitioner (GP) was 1.0 (3.4) years (**Table 2**). The majority of patients (72.4%) reported that less than a year had passed from the first symptoms of AA until a diagnosis by the GP, while 17.9% and 9.7% reported more than one- and two-years delay, respectively. More than half of the patients (66.9%) reported that they had symptoms of AA within the past 12 months. The mean (SD) current self-reported degree of AA was 7.4 (3.2) and the median (IQR) was 9 (5-10) on a numeric rating scale from 0-10.

General practitioners in Denmark are not trained in using methods such as trichoscopy, and to prevent misclassification of individuals with other forms of hair-loss, all patients included in our cohort had to be diagnosed with AA by a dermatologist. The relatively short time interval from onset of symptoms to contact with a GP indicates an urgency and need for diagnosis and intervention for patients with AA. Interestingly, the self-reported degree of AA was rather high (median 9), while on the other hand 46.9% of the patients reported that they were only missing 0 to 20% of scalp hair. This observation suggests that the subjective burden of AA may not directly correlate with objective measures.

### **Family history of AA**

When asked about history of AA in the family, approximately 5% reported that either a sibling or a parent had been diagnosed with AA. Furthermore, 4% and 3% reported that a grandparent or child had AA. A total of 179 patients (12%) had at least one first degree family member with AA. An increased incidence of AA in first-degree family members have previously been reported in up to 42% of patients. Furthermore, observational studies, twin studies and genome-wide association studies suggests a strong genetic component in pathogenesis of AA, similar to other autoimmune diseases.[24,25] The family history of AA may be

1  
2  
3  
4 underestimated in our cohort, as the condition is considered medically benign and patients with mild and/or  
5  
6 transient symptoms may not have discussed it with their family members.  
7  
8  
9

## 10 11 12 **STRENGTHS AND LIMITATIONS** 13 14

15  
16 The AA extension in the Danish Skin Cohort represents a large group of patients with AA and provides an  
17  
18 opportunity to investigate a range of variables and patient reported outcomes longitudinally. The data may  
19  
20 also be linked with routinely collected healthcare data from the nationwide Danish registries and gives us a  
21  
22 unique opportunity to combine information on clinical manifestations of AA with pharmacological, socio-  
23  
24 demographic data, as well as possible comorbidity data that can be linked to this cohort on individual-level.  
25  
26 As with all questionnaire-based studies, this cohort carries a risk of recall bias, however the majority of  
27  
28 patients had symptoms within the past 12 months of participation, increasing the chance of a more accurate  
29  
30 recollection. We expect a low risk of misclassification of patients, as all participants have been diagnosed by  
31  
32 a dermatologist. We sought to reduce the risk of participation bias by not informing about the content of the  
33  
34 project before accepting to participate, however it is likely that some demographic groups are better  
35  
36 represented than others, resulting in a skewed gender and/or age distribution. The overall response rate was  
37  
38 46.7%, which is in the normal range for surveys in Denmark. The DLQI data must be interpreted with  
39  
40 caution, as the questionnaire is designed for one week recall period and some questions are more suitable for  
41  
42 other skin conditions such as psoriasis rather than AA. Furthermore, data concerning Fitzpatrick skin type  
43  
44 may not be extrapolated to countries with other ethnic compositions.  
45  
46  
47  
48  
49  
50

## 51 **COLLABORATION** 52 53

54  
55 The AA cohort was established to bring new insight in disease characteristics as well as the impact of AA on  
56  
57 different aspects of life including social, occupational and psychological behaviour. By adding longitudinal  
58  
59 follow-up data, we hope to describe the disease trajectory and prognosis of AA, as well as explore the burden  
60

1  
2  
3  
4 of disease over time. Furthermore, by adding routinely collected data we will be able to investigate  
5  
6 comorbidities and efficacy of pharmacological interventions. A deepened and more holistic understanding of  
7  
8 AA will hopefully increase awareness of the disorder and facilitate personalized treatment strategies. Future  
9  
10 collaboration projects with other research groups are of interest, especially collaborations where study results  
11  
12 may be replicated in other cohorts internationally.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

### Contributor statement

Dr. YMF Andersen: conception and design, planning, and interpretation of data, reporting of the work

Ms. L Nymand: conception and design, planning, interpretation of data, reporting of the work

Ms. AM DeLozier: conception and design, planning, interpretation of data, reporting of the work

Dr. R Bruge: conception and design, planning, interpretation of data, reporting of the work

Ms. E Edson-Heredia: conception and design, planning, interpretation of data, reporting of the work

Dr. A Egeberg: conception, design, planning, conduct, acquisition, analysis, and interpretation of data, reporting of the work

### Competing interests

Dr. Andersen has received research funding from Kgl Hofbundtmager Aage Bang Foundation and AP Moller Foundation. Ms. Nymand has nothing to declare. Dr. Burge, Mrs. Delozier and Mrs. Edson-Heredia are employees and stockholders of Eli Lilly and Company. Dr. Egeberg has received research funding from Pfizer, Eli Lilly, Novartis, Bristol-Myers Squibb, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Galápagos NV, Sun Pharmaceuticals, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, and Janssen Pharmaceuticals.

### Funding

Development of this manuscript was supported by Eli Lilly and Company.

### Study approvals

The project was approved by the Danish Data Protection Agency, and registered at the Capital Region's inventory (VD-2018-286).

### Data sharing statements

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

There are no plans on sharing the raw data, however, data from the Danish Skin Cohort will be available for research collaborations upon obtaining the necessary legal approvals.

For peer review only

## References

- 1 Mirzoyev SA, Schrum AG, Davis MDP, *et al.* Lifetime incidence risk of alopecia areata estimated at 2.1% by rochester epidemiology project, 1990-2009. *J. Invest. Dermatol.* 2014;**134**:1141–2. doi:10.1038/jid.2013.464
- 2 Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: A systematic review. *Clin. Cosmet. Investig. Dermatol.* 2015;**8**:397–403. doi:10.2147/CCID.S53985
- 3 Gilhar A, Etzioni A, Paus R. Alopecia Areata. *N Engl J Med* 2012;**366**:1515–25. doi:10.1056/NEJMra1103442
- 4 Chu SY, Chen YJ, Tseng WC, *et al.* Comorbidity profiles among patients with alopecia areata: The importance of onset age, a nationwide population-based study. *J Am Acad Dermatol* 2011;**65**:949–56. doi:10.1016/j.jaad.2010.08.032
- 5 Strazzulla LC, Wang EHC, Avila L, *et al.* Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis. *J Am Acad Dermatol* 2018;**78**:1–12. doi:10.1016/j.jaad.2017.04.1141
- 6 Islam N, Leung PSC, Huntley AC, *et al.* The autoimmune basis of alopecia areata: A comprehensive review. *Autoimmun Rev* 2015;**14**:81–9. doi:10.1016/j.autrev.2014.10.014
- 7 Egeberg A, Andersen YMF, Thyssen JP. Prevalence and characteristics of psoriasis in Denmark: Findings from the Danish skin cohort. *BMJ Open* 2019;**9**:e028116. doi:10.1136/bmjopen-2018-028116
- 8 Schmidt M, Schmidt SAJ, Sandegaard JL, *et al.* The Danish National Patient Registry: a review of content, data quality, and research potential. *Clin Epidemiol* 2015;**7**:449–90. doi:10.2147/CLEP.S91125



- 1  
2  
3  
4 9 Wyrwich KW, Kitchen H, Knight S, *et al.* Development of the Scalp Hair Assessment  
5 PRO™ measure for alopecia areata. *Br J Dermatol* 2020;**183**:1065–72.  
6  
7  
8  
9 doi:10.1111/bjd.19024  
10  
11 10 Kyriakis K, Paltatzidou K, Kosma E, *et al.* Alopecia areata prevalence by gender and age. *J*  
12 *Eur Acad Dermatology Venereol* 2009;**23**:572–3. doi:10.1111/j.1468-3083.2008.02956.x  
13  
14  
15 11 Aşkın Ö, Koyuncu Z, Serdaroğlu S. Association of alopecia with self-esteem in children and  
16 adolescents. *Int J Adolesc Med Health* 2020;**1**. doi:10.1515/ijamh-2020-0100  
17  
18  
19  
20 12 Egeberg A, Griffiths CEM, Williams HC, *et al.* Clinical characteristics, symptoms and  
21 burden of psoriasis and atopic dermatitis in adults. *Br J Dermatol* 2020;**183**:128–38.  
22  
23  
24  
25  
26  
27 13 Gwillim EC, Jimenez J, Ali Y, *et al.* 205 Risk of ischemic heart disease in patients with  
28 alopecia areata: A large, urban, retrospective Midwestern US patient population study. *J*  
29 *Invest Dermatol* 2019;**139**:S35. doi:10.1016/j.jid.2019.03.281  
30  
31  
32  
33  
34 14 Huang KP, Joyce CJ, Topaz M, *et al.* Cardiovascular risk in patients with alopecia areata  
35 (AA): A propensity-matched retrospective analysis. *J Am Acad Dermatol* 2016;**75**:151–4.  
36  
37  
38  
39  
40  
41 15 Kang JH, Lin HC, Kao S, *et al.* Alopecia areata increases the risk of stroke: A 3-year follow-  
42 up study. *Sci Rep* 2015;**5**:1–6. doi:10.1038/srep11718  
43  
44  
45  
46 16 Dai YX, Yeh FY, Shen YJ, *et al.* Cigarette Smoking, Alcohol Consumption, and Risk of  
47 Alopecia Areata: A Population-Based Cohort Study in Taiwan. *Am J Clin Dermatol*  
48 2020;**21**:901–11. doi:10.1007/s40257-020-00547-7  
49  
50  
51  
52 17 Lee H, Jung SJ, Patel AB, *et al.* Racial characteristics of alopecia areata in the United States.  
53 *J Am Acad Dermatol* 2020;**83**:1064–70. doi:10.1016/j.jaad.2019.06.1300  
54  
55  
56  
57 18 Thompson JM, Park MK, Qureshi AA, *et al.* Race and Alopecia Areata amongst US Women.  
58  
59  
60

- 1  
2  
3  
4 *J Investig Dermatology Symp Proc* 2018;**19**:S47–50. doi:10.1016/j.jisp.2017.10.007
- 5  
6  
7 19 Roberts MH, Erdei E. Comparative United States autoimmune disease rates for 2010–2016  
8  
9 by sex, geographic region, and race. *Autoimmun Rev* 2020;**19**:102423.  
10  
11 doi:10.1016/j.autrev.2019.102423  
12
- 13  
14 20 Moroni L, Bianchi I, Lleo A. Geoepidemiology, gender and autoimmune disease. *Autoimmun*  
15  
16 *Rev* 2012;**11**:A386–92. doi:10.1016/j.autrev.2011.11.012  
17
- 18  
19 21 Rencz F, Gulácsi L, Péntek M, *et al.* Alopecia areata and health-related quality of life: a  
20  
21 systematic review and meta-analysis. *Br J Dermatol* 2016;**175**:561–71.  
22  
23 doi:10.1111/bjd.14497  
24
- 25  
26 22 Okhovat J-P, Marks DH, Manatis-Lornell A, *et al.* Association Between Alopecia Areata,  
27  
28 Anxiety, and Depression: A Systematic Review and Meta-analysis. *J Am Acad Dermatol*  
29  
30 Published Online First: 2019. doi:10.1016/j.jaad.2019.05.086  
31
- 32  
33 23 Dai YX, Tai YH, Chen CC, *et al.* Bidirectional association between alopecia areata and sleep  
34  
35 disorders: a population-based cohort study in Taiwan. *Sleep Med* 2020;**75**:112–6.  
36  
37 doi:10.1016/j.sleep.2020.06.015  
38
- 39  
40 24 Biran R, Zlotogorski A, Ramot Y. The genetics of alopecia areata: New approaches, new  
41  
42 findings, new treatments. *J Dermatol Sci* 2015;**78**:11–20. doi:10.1016/j.jdermsci.2015.01.004  
43
- 44  
45 25 Petukhova L, Duvic M, Hordinsky M, *et al.* Genome-wide association study in alopecia  
46  
47 areata implicates both innate and adaptive immunity. *Nature* 2010;**466**:113–7.  
48  
49 doi:10.1038/nature09114  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1 – Patient characteristics

	Alopecia Areata n=1494
<b>Age at inclusion, mean (SD)</b>	51.3 (16.0)
<b>Sex, n (%)</b>	
Female	1003 (67.1)
Male	491 (32.9)
<b>BMI, n (%)</b>	
<18.5	34 (2.3)
18.5 – 25	705 (47.2)
>25 – 30	522 (34.9)
>30 - 35	161 (10.8)
>35	72 (4.8)
<b>BMI, Mean (SD)</b>	25.8 (5.2)
<b>Smoking status, n (%)</b>	
Current daily smoker	205 (13.7)
Current occasional smoker	78 (5.2)
Former smoker	508 (34.0)
Never smoker	703 (47.1)
<b>Physical activity, n (%)</b>	
sedentary	294 (19.7)
moderate	814 (54.7)
vigorous	362 (24.3)
athletic	19 (1.3)
<b>Fitzpatrick skin type, n (%)</b>	
1	106 (7.1)
2	605 (40.5)
3	671 (44.9)
4	97 (6.5)
5	15 (1.0)
<b>DLQI, n (%)</b>	
0-2	1128 (75.5)
3-5	220 (14.7)
6-9	83 (5.6)
10-14	36 (2.4)
15-19	13 (0.9)
≥20	14 (0.9)
<b>DLQI, median (IQR)</b>	1 (0 - 2)

BMI, Body Mass Index; DLQI, Dermatology Life Quality Index;  
IQR, interquartile range; SD, standard deviation

**Table 2 – History of Alopecia Areata**

	<b>Alopecia Areata n=1494</b>
<b>Age at AA onset, mean (SD)</b>	32.72 (17.6)
<b>Years from onset of symptoms to diagnosis by a general practitioner</b>	
Mean (SD)	0.99 (3.4)
Less than one year, n (%)	105 (72.4)
One year, n (%)	26 (17.9)
Two or more years, n (%)	14 (9.7)
<b>Years from onset of symptoms to diagnosis by a dermatologist</b>	
Mean (SD)	1.18 (4.5)
Less than one year, n (%)	671 (68.5)
One year, n (%)	198 (20.2)
Two or more years, n (%)	110 (11.2)
<b>Did you have AA within the last 12 months? n (%)</b>	
Yes	741 (66.9)
<b>Patient reported current severity of AA, NRS 0-10</b>	
Mean (SD)	7.37 (3.2)
Median (IQR)	9 (5-1)
<b>Family history of AA, n (%)</b>	
Siblings	56 (5.1)
Mother	47 (4.2)
Father	59 (5.3)
Grand parents	43 (3.9)
Children	32 (2.9)
At least one 1. degree family with AA	179 (12.0)

AA, Alopecia Areata; IQR, interquartile range; NRS, Numeric rating scale; SD, standard deviation

**Table 3 – AA-specific patient reported outcomes**

	Alopecia Areata n=1494
<b>[PRO Measure for Eye Irritation] Please rate how irritated (e.g. itching, stinging, burning, or dry) either of your eyes have been in the past 7 days, n(%)</b>	
My eyes have not been irritated	828 (55.65)
My eyes have been a little irritated	436 (29.30)
My eyes have been moderately irritated	153 (10.28)
My eyes have been severely irritated	71 (4.77)
<b>[PRO Measure for Eyelashes] Look at your upper and lower eyelashes on both your eyes. Please rate your eyelashes, as they look today, n(%)</b>	
I have full eyelashes on each eyelid	481 (43.61)
I have a minimal gap or minimal gaps along the eyelids	203 (18.40)
I have a large gap or large gaps along the eyelids	64 (5.80)
I have no or barely any eyelash hair	355 (32.18)
<b>[PRO Measure for Eyebrows] Look at the hair in both of your eyebrows. Please rate your eyebrows, as they look today, n(%)</b>	
I have full eyebrows on each eye	412 (37.25)
I have a minimal gap(s) or a minimal amount of thinning in at least one of my eyebrows	180 (16.27)
I have a large gap(s) or a large amount of thinning in at least one of my eyebrows	114 (10.31)
I have no or barely any eyebrow hairs	400 (36.17)
<b>[PRO Measure for Nail Appearance] Examine your fingernails and toenails. Please rate your fingernails and toenails, as they look today, n(%)</b>	
Nails are not at all damaged (e.g. pitted, rough, brittle, split)	522 (47.24)
At least one nail is a little damaged (e.g. pitted, rough, brittle, split)	303 (27.42)
At least one nail is moderately damaged (e.g. pitted, rough, brittle, split)	193 (17.47)
At least one nail is very damaged (e.g. pitted, rough, brittle, split) or you have lost at least one nail	87 (7.87)
<b>[Scalp Hair Assessment PRO] Use mirrors to look at your entire scalp. Please rate the total area of your scalp that is missing hair right now, n(%)</b>	
No missing hair (0% of my scalp is missing hair; I have a full head of hair)	234 (21.16)
A limited area (1-20% of my scalp is missing hair)	284 (25.68)
A moderate area (21-49% of my scalp is missing hair)	132 (11.93)
A large area (50-94% of my scalp is missing hair)	109 (9.86)
Nearly all or all (95-100% of my scalp is missing hair)	347 (31.37)
PRO, patient reported outcome;	

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Supplementary table 1

## List of variables available from the baseline assessment interviews in the Danish Skin Cohort

Variable	Type	Choice	Details
Height	Continuous	Single	Centimetres
Weight	Continuous	Single	Kilograms
Smoking	Categorical	Single	Current daily smoker Current non-daily smoker Former smoker Never smoker
Alcohol use	Continuous	Single	Units of alcohol per week
Alcohol use	Categorical	Single	AUDIT-C for alcohol, questionnaire (multiple questions, one variable for each question)
Skin type	Categorical	Single	Fitzpatrick skin types 0-6
Leisure time activity level	Ordinal	Single	Athletic Vigorous Moderate Sedentary
Joint pain within last 7 days	Interval	Single	Numeric Rating Scale (0 to 10)
Skin pain within last 7 days	Interval	Single	Numeric Rating Scale (0 to 10)

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46	<p>Skin pruritus within last 3 days</p> <p>Trouble sleeping within last 3 days</p> <p>Age at AA onset</p> <p>Active AA in the past 12 months</p> <p>Family history of AA</p> <p>Current body surface area affected by AA at any point during the past 12 months affected by AA</p> <p>Largest body surface area affected by AA at any point during the past 12 months</p> <p>Largest body surface area affected by AA at any point during the past 12 months affected by AA at any point in your life</p> <p>Patient reported current disease severity</p> <p>Disease development/progression in the past 12 months</p>	<p>Interval</p> <p>Interval</p> <p>Continuous</p> <p>Dichotomous</p> <p>Categorical</p> <p>Interval</p> <p>Interval</p> <p>Interval</p> <p>Interval</p> <p>Categorical</p>	<p>Single</p> <p>Single</p> <p>Single</p> <p>Single</p> <p>Multiple</p> <p>Single</p> <p>Single</p> <p>Single</p> <p>Single</p> <p>Single</p>	<p>Numeric Rating Scale (0 to 10)</p> <p>Numeric Rating Scale (0 to 10)</p> <p>Age in years</p> <p>Yes / No</p> <p>Sibling Mother Father Grandparent Children</p> <p>0 to 100</p> <p>0 to 100</p> <p>0 to 100</p> <p>Numeric Rating Scale (0 to 10)</p> <p>AA has worsened a lot AA has worsened AA has remained unchanged AA has improved a little AA has improved a lot AA has gone into complete remission</p>
---	---	--	---	---



Number of disease flares in the past 12 months	Continuous	Single	A flare is defined as one or more consecutive days with significant worsening of symptoms requiring escalation of treatment or seeking additional medical advice
Time from first AA symptoms to first AA diagnosis by a physician	Continuous	Single	Time in years
Time from first AA symptoms to first AA diagnosis by a dermatologist	Continuous	Single	Time in years
Seasonal changes in severity	Categorical	Multiple	Worsens during spring Worsens during summer Worsens during fall Worsens during winter No seasonal variation
WPAI			Work productivity and activity index Multiple variables (one for each question)
EQ-5D-5L			EuroQoL 5 Dimensions 5 Levels Multiple variables (one for each question)
DLQI			Dermatology Life Quality Index Multiple variables (one for each question)
MFI-20			Multidimensional Fatigue Inventory Multiple variables (one for each question)
AASIS			Alopecia Areata Symptom Impact Scale Multiple variables (one for each question)
PRO Measure for Eye Irritation	Ordinal	Single	Please rate how irritated (e.g. itching, stinging, burning, or dry) either of your eyes have been in the past 7 days.

			<p>My eyes have not been irritated</p> <p>My eyes have been a little irritated</p> <p>My eyes have been moderately irritated</p> <p>My eyes have been severely irritated</p>
PRO Measure for Eyebrows	Ordinal	Single	<p>Look at the hair in both of your eyebrows. Please rate your eyebrows, as they look today. This question asks about gap(s) in your eyebrows or thinning in your eyebrows. If you have gap(s) in your eyebrows and thinning in your eyebrows, please choose your answer based on the type of hair loss that bothers you the most.</p> <p>I have full eyebrows on each eye</p> <p>I have a minimal gap(s) or a minimal amount of thinning in at least one of my eyebrows</p> <p>I have a large gap(s) or a large amount of thinning in at least one of my eyebrows</p> <p>I have no or barely any eyebrow hairs</p>
PRO Measure for Eyelashes	Ordinal	Single	<p>Look at your upper and lower eyelashes on both your eyes. Please rate your eyelashes, as they look today.</p> <p>I have full eyelashes on each eyelid</p> <p>I have a minimal gap or minimal gaps along the eyelids</p> <p>I have a large gap or large gaps along the eyelids</p> <p>I have no or barely any eyelash hair</p>
PRO Measure for Nail Appearance	Ordinal	Single	<p>Examine your fingernails and toenails. Please rate your fingernails and toenails, as they look today.</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

			<p>Nails are not at all damaged (e.g. pitted, rough, brittle, split)</p> <p>At least one nail is a little damaged (e.g. pitted, rough, brittle, split)</p> <p>At least one nail is moderately damaged (e.g. pitted, rough, brittle, split)</p> <p>At least one nail is very damaged (e.g. pitted, rough, brittle, split) or you have lost at least one nail</p>
Scalp Hair Assessment PRO	Ordinal	Single	<p>Use mirrors to look at your entire scalp.</p> <p>Please rate the total area of your scalp that is missing hair right now.</p> <p>Areas of vellus hair (peach fuzz or baby hair) should also be considered as missing hair.</p> <p>No missing hair (0% of my scalp is missing hair; I have a full head of hair)</p> <p>A limited area (1-20% of my scalp is missing hair)</p> <p>A moderate area (21-49% of my scalp is missing hair)</p> <p>A large area (50-94% of my scalp is missing hair)</p> <p>Nearly all or all (95-100% of my scalp is missing hair)</p>

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7
Bias	9	Describe any efforts to address potential sources of bias	NA
Study size	10	Explain how the study size was arrived at	7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Table
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6-7
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	NA
		(d) If applicable, describe analytical methods taking account of sampling strategy	Na
		(e) Describe any sensitivity analyses	Na
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	7
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8-11
		(b) Indicate number of participants with missing data for each variable of interest	
Outcome data	15*	Report numbers of outcome events or summary measures	8-11
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	8-11

		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	11-12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12
Generalisability	21	Discuss the generalisability (external validity) of the study results	12
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	None

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Cohort profile: Patient characteristics and disease burden of alopecia areata in the Danish Skin Cohort

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-053137.R2
Article Type:	Cohort profile
Date Submitted by the Author:	20-Jan-2022
Complete List of Authors:	Andersen, Yuki M F; University of Copenhagen, Department of Dermatology and Allergy Nymand, Lea; University of Copenhagen, Department of Dermatology DeLozier, Amy M.; Eli Lilly and Company Burge, Russel T.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, United States , Global Health Outcomes Edson-Heredia, E.; Eli Lilly Egeberg, A; Bispebjerg Hospital, Department of Dermatology
<b>Primary Subject Heading</b>:	Dermatology
Secondary Subject Heading:	Epidemiology
Keywords:	DERMATOLOGY, Dermatological epidemiology < DERMATOLOGY, Dermatology < INTERNAL MEDICINE

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

**Title Page****Title**

Cohort profile: Patient characteristics and disease burden of alopecia areata in the Danish Skin Cohort

**Manuscript word, table and figure count**

2,729 words, 3 tables, 0 figures

**Authors full names, departments, and institutions**

Yuki M F Andersen<sup>1</sup> MD, PhD; Lea K Nymand<sup>2</sup> MSc; Amy M. DeLozier<sup>3</sup> MPH; Russel Burge<sup>3,4</sup> PhD; Emily Edson-Heredia<sup>3</sup> MPH; Alexander Egeberg<sup>2</sup> MD, PhD, DMSc

- 1) Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
- 2) Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark
- 3) Eli Lilly and Company, Indianapolis, Indiana, United States
- 4) Division of Pharmaceutical Sciences, University of Cincinnati, Cincinnati, OH, United States

**Corresponding author**

Yuki Andersen, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Kildegårdsvej 28, 2900 Hellerup, Denmark

Telephone: (0045) 38673157

E-mail: yuki.maria.fukuda.andersen.01@regionh.dk



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Abstract (299/300)

### Purpose

Alopecia areata (AA) is a common disorder of patchy hair loss which carries a substantial psychological burden for patients. The current understanding of AA prevalence, disease course and burden is limited, and further research is needed to improve patient care. This prospective cohort of AA patients within the Danish Skin Cohort was established to provide data that can serve as a tool in future studies of e.g., AA epidemiology and disease burden.

### Participants

A total of 1494 patients with dermatologist-verified AA were included in the cohort. Patients were invited and included through electronic or phone-based questionnaires. Information regarding demographics, biometrics, lifestyle factors, skin type, AA onset and development, health related quality of life, and self-reported severity assessment was collected.

### Findings to date

The mean (SD) age of AA onset was 32.7 (17.6) years. The mean body mass index and history of cigarette smoking was comparable with the general population. The majority (92.5%) of participants were Caucasian. In total, 72.4% of patients received their diagnosis by a physician within a year after onset of symptoms, and 66.9% reported to still have symptoms of AA within the past year. A total of 12% reported to have a first-degree family member with AA. In total, 31.4% of patients were missing all or nearly all hairs on their scalp, 32.2% had no or barely no eyelashes and 36.2% had no or barely no eyebrow hairs. Overall, most

1  
2  
3  
4 patients (55.7%) did not experience irritated eyes, but 30% reported slight eye irritation, and 47.2%  
5  
6 reported no damage to finger- or toenails.  
7  
8  
9

## 10 11 12 **Future plans**

13  
14  
15 Observational studies regarding comorbidities, psychosocial burden of AA and efficacy of pharmacological  
16  
17 interventions will be carried out, and additional data will be linked from nationwide registries of routinely  
18  
19 collected data. Furthermore, follow-up survey data will be added for longitudinal analyses.  
20  
21  
22

## 23 24 25 **Strengths and limitations of this study**

- 26  
27  
28  
29
- 30 • This cohort was interviewed by trained professionals in a standardized manner.
  - 31
  - 32 • The diagnosis of AA was verified by dermatologists in all patients.
  - 33
  - 34 • Patients were not informed of the topic and contents of the projects until they agreed to
  - 35
  - 36 participate, thereby reducing participation bias.
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42 • Patients were not interviewed about comorbidities, since such information can be obtained
  - 43
  - 44 by linking patients' responses with nationwide registries in Denmark.
  - 45
  - 46
  - 47
  - 48
  - 49 • Risk of recall bias is a limitation as the cohort is based on patient interviews.
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60

## INTRODUCTION

Alopecia areata (AA) is a common hair loss disorder with a life-time prevalence estimated to be approximately 2% in the US.[1,2] The condition affects both children and adults and typically presents as well-demarcated patches of hair loss in the scalp without significant visible inflammation or scarring. AA may progress to involve the entire scalp (alopecia totalis) or all scalp and body hairs (alopecia universalis).[3] The course of AA is unpredictable, and regrowth and relapse may occur, alternately. The condition is furthermore associated with atopic predispositions and various autoimmune diseases, in particular thyroid disease and vitiligo.[4] The exact pathophysiology of AA is unknown, however it is considered to be a T-cell mediated autoimmune condition where hair follicles enter the telogen phase (resting phase) prematurely, resulting in hair loss.[5,6]

Although AA is a common condition in dermatological practice, understanding of prevalence, prognosis, and impact on patients' lives remain scarce and the condition is understudied compared with e.g., atopic dermatitis and psoriasis. A detailed description of patients with AA and establishment of a prospective cohort will enable better understanding of AA and secure an increased recognition within the field of dermatological research. Furthermore, a well-described patient cohort may serve as a tool in future research and assessment of efficacy of future emerging therapies. The aim of the current paper was to present the establishment of a new AA cohort within the Danish Skin Cohort and to describe patient demographics and characteristics.

## COHORT DESCRIPTION

1  
2  
3  
4 This study was a population-based cross-sectional study using data from the extended Danish Skin Cohort.  
5  
6 Information regarding patient characteristics, disease onset, severity and patient-reported outcomes were  
7  
8 collected using questionnaires or structured interviews.  
9  
10  
11  
12  
13  
14  
15  
16

### 17 **The Danish Skin Cohort**

18  
19  
20 The Danish Skin Cohort was established in 2018 to study the prevalence, morphology, and burden of skin  
21  
22 diseases in Denmark.[7] The cohort originally consisted of three independent samples. Sample A  
23  
24 representing a random sample of general population adults in Denmark. Sample B and C representing  
25  
26 groups of patients with a dermatologist verified plaque psoriasis, and atopic dermatitis, respectively. All  
27  
28 participants in this prospective cohort were adults ( $\geq 18$  years) at the time of inclusion. In 2020, the Danish  
29  
30 Skin Cohort was expanded to also include patients with AA, hidradenitis suppurativa, and rosacea. Patients  
31  
32 with AA were identified using the Danish National Patient Registry. The registry contains information on all  
33  
34 hospital contacts (both in- and outpatient) in Denmark, as well as a number of private practice dermatology  
35  
36 clinics. Each visit is coded with a diagnostic code based on the International Classification of Diseases (ICD)  
37  
38 system.[8] All patients with an ICD-10 code for AA recorded in the Danish National Patient Registry at least  
39  
40 once during adulthood (i.e. after their 18<sup>th</sup> birthday) were identified and invited to participate in the cohort.  
41  
42 Participants were not informed that the research project was related to skin diseases until they had agreed  
43  
44 to participate and were simply informed that the research was “regarding people in the Danish  
45  
46 population”. This was to reduce the risk of participation bias. Study individuals had the opportunity to  
47  
48 withdraw from participation upon accepting the invitation, and throughout the study. A total of 3198 adults  
49  
50 with a diagnosis of AA were invited to participate.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Ethical approval

Review of an ethics committee is not required in Denmark for studies not involving human tissue.

## Patient and Public Involvement

Patients were not involved in the development of the research questions or outcome measures, but all responses to these interviews were provided by AA patients.

## Patient interviews

All communications from the government and official institutions in Denmark are sent to citizens to a personal and secure digital mailbox. Citizens are notified through a text message or email and they are obliged to check the mailbox on a regular basis. Individuals who were eligible to participate in the Danish Skin Cohort received an invitation to participate and were interviewed through a digital questionnaire. In case of non-response, individuals were sent a reminder after one week, and were contacted by phone or mail up to a total of five times. In case of a phone interview, participants were interviewed in a structured manner by professional researchers.

Information on patient demographics including age at participation, sex, height in cm, weight in kg, smoking history and quantity, current alcohol consumption, level of physical activity, and Fitzpatrick skin type (range 1 to 5) was obtained. Other variables included age of AA onset, time from onset to diagnosis by physician, time from onset to dermatologist referral, AA symptoms and activity during the past 12 months, family history of AA, episodes of flares or worsening in AA symptoms during the past 12 months, seasonal variation in symptoms, and the affected hair loss in percentages. Current self-perceived severity of AA symptoms was recorded using a numeric rating scale (NRS) from 0 to 10, where 10 represents the highest degree of severity. Additional patient-reported outcomes included Dermatology Life Quality Index (DLQI),

1  
2  
3  
4 Work Productivity and Activity Index (WPAI), EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L), and the  
5  
6 Multidimensional Fatigue Inventory-20 (MFI-20). Additional patient reported outcome (PRO) measures  
7  
8 included assessment of nail appearance, eye irritation, affection of eye lashes, involvement of eyebrows,  
9  
10 and scalp hair assessment.[9] A measure of eye irritation, rather than a measure of dry eyes, was included  
11  
12 since this measure was specifically developed and used in clinical trials of novel AA therapies, thus enabling  
13  
14 direct comparison with clinical trial results (NCT03899259). A full list of the obtained information is  
15  
16 available from **Supplementary Table 1**.  
17  
18  
19  
20  
21  
22  
23  
24  
25

### 26 **Statistical analysis**

27  
28  
29 Characteristics of patients with AA were presented using summary statistics. Continuous variables with a  
30  
31 normal distribution were presented as means and standard deviations (SD), while medians and  
32  
33 interquartile ranges (IQR) were presented for non-normal continuous variables. Categorical variables were  
34  
35 presented as frequencies and percentages. As the data were purely descriptive no test for significance was  
36  
37 carried out.  
38  
39  
40  
41  
42  
43

### 44 **Patient demographics**

45  
46  
47 A total of 1494 patients with AA accepted the invitation and were included. The mean age (SD) at inclusion  
48  
49 was 51.3 (16.0) years, with a strong female predominance of 67% (**Table 1**). The mean age (SD) at AA onset  
50  
51 was 32.7 (17.6) years (**Table 2**). Previous epidemiological studies have shown contradicting results  
52  
53 regarding the gender distribution among AA patients, where some studies show an equal distribution,  
54  
55 while others show a greater representation of either sexes.[1,2,10] The gender distribution may vary  
56  
57 according to study population and study design. Our observation may partially reflect a higher awareness of  
58  
59  
60

1  
2  
3  
4 hair loss among women. Furthermore, the skewed distribution may represent different response rates in  
5  
6 different demographic groups, where middle aged women tend to have higher response rates than young  
7  
8 men, for example. The reported age of AA onset in our cohort is similar to previous reports, where the  
9  
10 majority of patients tend to experience first onset of AA before the age of 40. A literature review has  
11  
12 estimated that the mean age of onset of AA is between 25.2 and 36.3 years.[2] Hair loss in children,  
13  
14 adolescents and young adults often has a big impact on the patients' self-esteem, and therefore less likely  
15  
16 to be affected by recall bias.[11]  
17  
18  
19  
20  
21  
22  
23

## 24 FINDINGS TO DATE

### 27 Body mass index and lifestyle factors

28  
29  
30 The mean (SD) BMI in the AA population was 25.8 (5.2). According to World Health Organization  
31  
32 classification of BMI, 2.3% were classified as underweight, 47.2% as normal weight, 34.9% as overweight  
33  
34 10.8% as obese and 4.8% as morbidly obese. Almost half of the patients had never smoked (47.1%), while  
35  
36 34.0% and 19.0% were former and current smokers, respectively. Furthermore, 54.7% rated themselves to  
37  
38 having a moderate physical activity level, while 24.3% and 1.3% reported a vigorous and athletic physical  
39  
40 activity level, respectively. Lastly, 19.7% reported a sedentary lifestyle.  
41  
42  
43  
44

45 In comparison, patients from the Danish Skin Cohort with psoriasis have a slightly higher mean (SD) BMI of  
46  
47 27.5 (6.5), while patients with atopic dermatitis have a similar mean (SD) BMI of 25.9 (5.6) (data on  
48  
49 file).[12] The prevalence of cigarette smoking in patients with AA was comparable with the general  
50  
51 population and lower than in patients with psoriasis in the Danish Skin Cohort.[12] The psychological stress  
52  
53 of having AA may influence patients' smoking habits, however the low mean age at onset could explain why  
54  
55 AA patients resemble the general population. Traditionally, AA is not considered a disease associated with  
56  
57 obesity and lifestyle related risk factors like e.g., patients with psoriasis. The current evidence on the  
58  
59  
60



1  
2  
3  
4 cardiovascular risk in patients with AA is limited and studies show conflicting results.[13–15] Cigarette  
5  
6 smoking was found to be associated with an increased risk of AA in a recent cohort study from Taiwan,  
7  
8 however further studies are needed to establish a relationship.[16]  
9  
10

### 11 12 13 14 15 **Fitzpatrick skin type**

16  
17  
18 We found that the majority (92.5%) of patients with AA in our cohort reported a Fitzpatrick skin type 1, 2 or  
19  
20 3. Only 6.5% and 1.0%, respectively reported a skin type 4 and 5. To our knowledge, no data on skin type  
21  
22 distribution is published on the Danish general population, therefore we lack a comparison group for this  
23  
24 outcome.  
25

26  
27 Racial disparities seem to exist in the prevalence of AA, and recent US epidemiologic studies have reported  
28  
29 that African Americans have a higher odds of AA, while Asians have a lower odds of AA compared with  
30  
31 Caucasians.[17,18] Furthermore, differences in disease prevalence according to geographical location and  
32  
33 ethnicity is well described in autoimmune diseases such as lupus erythematosus, rheumatoid arthritis and  
34  
35 multiple sclerosis.[19,20] The Danish population is considered to be primarily Caucasian, thus not  
36  
37 representative for investigating this characteristic of AA.  
38  
39  
40  
41  
42  
43  
44

### 45 **Dermatology Life Quality Index**

46  
47  
48 Patients with AA in our cohort reported a mean (SD) DLQI of 2.1 (3.7) and median (IQR) DLQI of 1 (0-2).

49  
50 DLQI is a broadly used and validated outcome to measure the impact of dermatological diseases on  
51  
52 patients' quality of life. The score ranges from 0 to 30, where a high score signifies a high impact on health-  
53  
54 related quality of life. We found a remarkably low DLQI in our AA cohort. One reason could be that while  
55  
56 patients with active progressive disease may be highly affected, patients with a steady state may be less  
57  
58  
59  
60

1  
2  
3  
4 affected by AA at the time of the questionnaire. Furthermore, the DLQI system is not designed specifically  
5  
6 for AA, and therefore some of the questions e.g., regarding itch, pain and physical activities are not suitable  
7  
8 for assessing the impact of AA. Arguably, DLQI is an inappropriate measure to thoroughly assess quality of  
9  
10 life related to AA, since it predominantly refers to cutaneous symptoms rather than symptoms associated  
11  
12 with hair loss.  
13  
14

15  
16 Although AA is neither life-threatening nor necessarily accompanied by physical pain, the condition may  
17  
18 have a significant impact on patients' quality of life. A systematic review and meta-analysis summarized  
19  
20 that the mean pooled DLQI score of patients with AA in three studies was 6.3 (95% CI 5.6-7.1).[21]  
21  
22 Interestingly, a dose-response relationship between severity of AA and health related quality of life is  
23  
24 uncertain,[21] possibly indicating that a small patch of hair loss may be just as impactful as a larger area of  
25  
26 hair loss. Patients with AA may carry a significant psychological burden due to the visible loss of hair and  
27  
28 the unpredictable disease course, which in turn may cause symptoms such as anxiety, depression, stress,  
29  
30 and sleep deprivation.[22,23] Hair loss may also carry a stigma relating to other forms of illnesses and  
31  
32 oncologic chemotherapy.  
33  
34  
35  
36

### 37 **AA-specific patient reported outcomes**

38  
39  
40 PROs related specifically to AA included information about eye irritation, missing eyelashes, missing  
41  
42 eyebrows, damaged nails and missing scalp hair. Overall, most patients in our cohort did not experience  
43  
44 irritated eyes (55.7%), however nearly 30% reported slight eye irritation, 10.3% and 4.8% had moderate  
45  
46 and severe eye irritation, respectively (**Table 3**). Most patients either reported having full eyelashes (43.6%)  
47  
48 or no/barely no eyelashes (32.2%) on each eyelid, and full eyebrows (37.3%) or no/barely no eyebrow hairs  
49  
50 (36.2%). When rating the finger- or toenails most patients (47.2%) answered that the nails were not at all  
51  
52 damaged (**Table 3**). Notably however, most people (31.4%) were missing nearly all or all scalp hair (95-  
53  
54 100% of the scalp is missing hair), suggesting that a high proportion of patients had severe scalp disease.  
55  
56  
57  
58

### 59 **AA diagnosis**

1  
2  
3  
4 The mean (SD) time from onset of symptoms to diagnosis at a general practitioner (GP) was 1.0 (3.4) years  
5  
6 **(Table 2)**. The majority of patients (72.4%) reported that less than a year had passed from the first  
7  
8 symptoms of AA until a diagnosis by the GP, while 17.9% and 9.7% reported more than one- and two-years  
9  
10 delay, respectively. More than half of the patients (66.9%) reported that they had symptoms of AA within  
11  
12 the past 12 months. The mean (SD) current self-reported degree of AA was 7.4 (3.2) and the median (IQR)  
13  
14 was 9 (5-10) on a numeric rating scale from 0-10.  
15  
16

17  
18 General practitioners in Denmark are not trained in using methods such as trichoscopy, and to prevent  
19  
20 misclassification of individuals with other forms of hair-loss, all patients included in our cohort had to be  
21  
22 diagnosed with AA by a dermatologist. The relatively short time interval from onset of symptoms to contact  
23  
24 with a GP indicates an urgency and need for diagnosis and intervention for patients with AA. Interestingly,  
25  
26 the self-reported degree of AA was rather high (median 9), while on the other hand 46.9% of the patients  
27  
28 reported that they were only missing 0 to 20% of scalp hair. This observation suggests that the subjective  
29  
30 burden of AA may not directly correlate with objective measures.  
31  
32  
33  
34  
35  
36  
37

### 38 **Family history of AA**

39  
40  
41 When asked about history of AA in the family, approximately 5% reported that either a sibling or a parent  
42  
43 had been diagnosed with AA. Furthermore, 4% and 3% reported that a grandparent or child had AA. A total  
44  
45 of 179 patients (12%) had at least one first degree family member with AA. An increased incidence of AA in  
46  
47 first-degree family members have previously been reported in up to 42% of patients. Furthermore,  
48  
49 observational studies, twin studies and genome-wide association studies suggests a strong genetic  
50  
51 component in pathogenesis of AA, similar to other autoimmune diseases.[24,25] The family history of AA  
52  
53 may be underestimated in our cohort, as the condition is considered medically benign and patients with  
54  
55 mild and/or transient symptoms may not have discussed it with their family members.  
56  
57  
58  
59  
60

## STRENGTHS AND LIMITATIONS

The AA extension in the Danish Skin Cohort represents a large group of patients with AA and provides an opportunity to investigate a range of variables and patient reported outcomes longitudinally. The data may also be linked with routinely collected healthcare data from the nationwide Danish registries and gives us a unique opportunity to combine information on clinical manifestations of AA with pharmacological, socio-demographic data on individual-level. Patients were not interviewed about comorbidities, since information on comorbidities can be obtained on individual-level by linking patients questionnaire responses with our nationwide registries in Denmark. As with all questionnaire-based studies, this cohort carries a risk of recall bias, however the majority of patients had symptoms within the past 12 months of participation, increasing the chance of a more accurate recollection. We expect a low risk of misclassification of patients, as all participants have been diagnosed by a dermatologist. We sought to reduce the risk of participation bias by not informing about the content of the project before accepting to participate, however it is likely that some demographic groups are better represented than others, resulting in a skewed gender and/or age distribution. The overall response rate was 46.7%, which is in the normal range for surveys in Denmark. The DLQI data must be interpreted with caution, as the questionnaire is designed for one week recall period and some questions are more suitable for other skin conditions such as psoriasis rather than AA. Furthermore, data concerning Fitzpatrick skin type may not be extrapolated to countries with other ethnic compositions.

## COLLABORATION

The AA cohort was established to bring new insight in disease characteristics as well as the impact of AA on different aspects of life including social, occupational and psychological behaviour. By adding longitudinal

1  
2  
3  
4 follow-up data, we hope to describe the disease trajectory and prognosis of AA, as well as explore the  
5  
6 burden of disease over time. Furthermore, by adding routinely collected data we will be able to investigate  
7  
8 comorbidities and efficacy of pharmacological interventions. A deepened and more holistic understanding  
9  
10 of AA will hopefully increase awareness of the disorder and facilitate personalized treatment strategies.  
11  
12  
13 Future collaboration projects with other research groups are of interest, especially collaborations where  
14  
15 study results may be replicated in other cohorts internationally.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

### Contributor statement

Dr. YMF Andersen: conception and design, planning, and interpretation of data, reporting of the work

Ms. L Nymand: conception and design, planning, interpretation of data, reporting of the work

Ms. AM DeLozier: conception and design, planning, interpretation of data, reporting of the work

Dr. R Burge: conception and design, planning, interpretation of data, reporting of the work

Ms. E Edson-Heredia: conception and design, planning, interpretation of data, reporting of the work

Dr. A Egeberg: conception, design, planning, conduct, acquisition, analysis, and interpretation of data, reporting of the work

### Competing interests

Dr. Andersen has received research funding from Kgl Hofbundtmager Aage Bang Foundation and AP Moller Foundation. Ms. Nymand has nothing to declare. Dr. Burge, Mrs. DeLozier and Mrs. Edson-Heredia are employees and stockholders of Eli Lilly and Company. Dr. Egeberg has received research funding from Pfizer, Eli Lilly, Novartis, Bristol-Myers Squibb, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Galápagos NV, Sun Pharmaceuticals, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, and Janssen Pharmaceuticals.

### Funding

Development of this manuscript was supported by Eli Lilly and Company.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **Study approvals**

The project was approved by the Danish Data Protection Agency, and registered at the Capital Region's inventory (VD-2018-286).

### **Data sharing statements**

There are no plans on sharing the raw data, however, data from the Danish Skin Cohort will be available for research collaborations upon obtaining the necessary legal approvals.

## References

- 1 Mirzoyev SA, Schrum AG, Davis MDP, *et al*. Lifetime incidence risk of alopecia areata estimated at 2.1% by rochester epidemiology project, 1990-2009. *J. Invest. Dermatol.* 2014;**134**:1141–2. doi:10.1038/jid.2013.464
- 2 Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: A systematic review. *Clin. Cosmet. Investig. Dermatol.* 2015;**8**:397–403. doi:10.2147/CCID.S53985
- 3 Gilhar A, Etzioni A, Paus R. Alopecia Areata. *N Engl J Med* 2012;**366**:1515–25. doi:10.1056/NEJMra1103442
- 4 Chu SY, Chen YJ, Tseng WC, *et al*. Comorbidity profiles among patients with alopecia areata: The importance of onset age, a nationwide population-based study. *J Am Acad Dermatol* 2011;**65**:949–56. doi:10.1016/j.jaad.2010.08.032
- 5 Strazzulla LC, Wang EHC, Avila L, *et al*. Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis. *J Am Acad Dermatol* 2018;**78**:1–12. doi:10.1016/j.jaad.2017.04.1141
- 6 Islam N, Leung PSC, Huntley AC, *et al*. The autoimmune basis of alopecia areata: A comprehensive review. *Autoimmun Rev* 2015;**14**:81–9. doi:10.1016/j.autrev.2014.10.014
- 7 Egeberg A, Andersen YMF, Thyssen JP. Prevalence and characteristics of psoriasis in Denmark: Findings from the Danish skin cohort. *BMJ Open* 2019;**9**:e028116. doi:10.1136/bmjopen-2018-028116
- 8 Schmidt M, Schmidt SAJ, Sandegaard JL, *et al*. The Danish National Patient Registry: a review of



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

content, data quality, and research potential. *Clin Epidemiol* 2015;**7**:449–90.

doi:10.2147/CLEP.S91125

9 Wyrwich KW, Kitchen H, Knight S, *et al.* Development of the Scalp Hair Assessment PRO™ measure  
10 for alopecia areata. *Br J Dermatol* 2020;**183**:1065–72. doi:10.1111/bjd.19024

10 Kyriakis K, Paltatzidou K, Kosma E, *et al.* Alopecia areata prevalence by gender and age. *J Eur Acad*  
11 *Dermatology Venereol* 2009;**23**:572–3. doi:10.1111/j.1468-3083.2008.02956.x

11 Aşkın Ö, Koyuncu Z, Serdaroğlu S. Association of alopecia with self-esteem in children and  
12 adolescents. *Int J Adolesc Med Health* 2020;**1**. doi:10.1515/ijamh-2020-0100

12 Egeberg A, Griffiths CEM, Williams HC, *et al.* Clinical characteristics, symptoms and burden of  
13 psoriasis and atopic dermatitis in adults. *Br J Dermatol* 2020;**183**:128–38. doi:10.1111/bjd.18622

13 Gwillim EC, Jimenez J, Ali Y, *et al.* 205 Risk of ischemic heart disease in patients with alopecia areata:  
14 A large, urban, retrospective Midwestern US patient population study. *J Invest Dermatol*  
15 2019;**139**:S35. doi:10.1016/j.jid.2019.03.281

14 Huang KP, Joyce CJ, Topaz M, *et al.* Cardiovascular risk in patients with alopecia areata (AA): A  
15 propensity-matched retrospective analysis. *J Am Acad Dermatol* 2016;**75**:151–4.  
16 doi:10.1016/j.jaad.2016.02.1234

15 Kang JH, Lin HC, Kao S, *et al.* Alopecia areata increases the risk of stroke: A 3-year follow-up study.  
16 *Sci Rep* 2015;**5**:1–6. doi:10.1038/srep11718

16 Dai YX, Yeh FY, Shen YJ, *et al.* Cigarette Smoking, Alcohol Consumption, and Risk of Alopecia Areata:  
17 A Population-Based Cohort Study in Taiwan. *Am J Clin Dermatol* 2020;**21**:901–11.  
18 doi:10.1007/s40257-020-00547-7

17 Lee H, Jung SJ, Patel AB, *et al.* Racial characteristics of alopecia areata in the United States. *J Am*

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- Acad Dermatol* 2020;**83**:1064–70. doi:10.1016/j.jaad.2019.06.1300
- 18 Thompson JM, Park MK, Qureshi AA, *et al.* Race and Alopecia Areata amongst US Women. *J Investig Dermatol Symp Proc* 2018;**19**:S47–50. doi:10.1016/j.jisp.2017.10.007
- 19 Roberts MH, Erdei E. Comparative United States autoimmune disease rates for 2010–2016 by sex, geographic region, and race. *Autoimmun Rev* 2020;**19**:102423. doi:10.1016/j.autrev.2019.102423
- 20 Moroni L, Bianchi I, Lleo A. Geoepidemiology, gender and autoimmune disease. *Autoimmun Rev* 2012;**11**:A386–92. doi:10.1016/j.autrev.2011.11.012
- 21 Rencz F, Gulácsi L, Péntek M, *et al.* Alopecia areata and health-related quality of life: a systematic review and meta-analysis. *Br J Dermatol* 2016;**175**:561–71. doi:10.1111/bjd.14497
- 22 Okhovat J-P, Marks DH, Manatis-Lornell A, *et al.* Association Between Alopecia Areata, Anxiety, and Depression: A Systematic Review and Meta-analysis. *J Am Acad Dermatol* Published Online First: 2019. doi:10.1016/j.jaad.2019.05.086
- 23 Dai YX, Tai YH, Chen CC, *et al.* Bidirectional association between alopecia areata and sleep disorders: a population-based cohort study in Taiwan. *Sleep Med* 2020;**75**:112–6. doi:10.1016/j.sleep.2020.06.015
- 24 Biran R, Zlotogorski A, Ramot Y. The genetics of alopecia areata: New approaches, new findings, new treatments. *J Dermatol Sci* 2015;**78**:11–20. doi:10.1016/j.jdermsci.2015.01.004
- 25 Petukhova L, Duvic M, Hordinsky M, *et al.* Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. *Nature* 2010;**466**:113–7. doi:10.1038/nature09114

Table 1 – Patient characteristics

## Alopecia Areata

n=1494

<b>Age at inclusion, mean (SD)</b>	51.3 (16.0)
<b>Sex, n (%)</b>	
Female	1003 (67.1)
Male	491 (32.9)
<b>BMI, n (%)</b>	
<18.5	34 (2.3)
18.5 – 25	705 (47.2)
>25 – 30	522 (34.9)
>30 - 35	161 (10.8)
>35	72 (4.8)
<b>BMI, Mean (SD)</b>	25.8 (5.2)
<b>Smoking status, n (%)</b>	
Current daily smoker	205 (13.7)
Current occasional smoker	78 (5.2)
Former smoker	508 (34.0)
Never smoker	703 (47.1)
<b>Physical activity, n (%)</b>	
sedentary	294 (19.7)
moderate	814 (54.7)
vigorous	362 (24.3)
athletic	19 (1.3)
<b>Fitzpatrick skin type, n (%)</b>	
1	106 (7.1)
2	605 (40.5)
3	671 (44.9)
4	97 (6.5)
5	15 (1.0)
<b>DLQI, n (%)</b>	
0-2	1128 (75.5)
3-5	220 (14.7)
6-9	83 (5.6)
10-14	36 (2.4)

15-19	13 (0.9)
≥20	14 (0.9)
<b>DLQI, median (IQR)</b>	<b>1 (0 - 2)</b>

---

BMI, Body Mass Index; DLQI, Dermatology Life Quality Index;  
IQR, interquartile range; SD, standard deviation

For peer review only

**Table 2 – History of Alopecia Areata**

	<b>Alopecia Areata</b>
	<b>n=1494</b>
<b>Age at AA onset, mean (SD)</b>	32.72 (17.6)
<b>Years from onset of symptoms to diagnosis by a general practitioner</b>	
Mean (SD)	0.99 (3.4)
Less than one year, n (%)	105 (72.4)
One year, n (%)	26 (17.9)
Two or more years, n (%)	14 (9.7)
<b>Years from onset of symptoms to diagnosis by a dermatologist</b>	
Mean (SD)	1.18 (4.5)
Less than one year, n (%)	671 (68.5)
One year, n (%)	198 (20.2)
Two or more years, n (%)	110 (11.2)
<b>Did you have AA within the last 12 months? n (%)</b>	
Yes	741 (66.9)
<b>Patient reported current severity of AA, NRS 0-10</b>	
Mean (SD)	7.37 (3.2)
Median (IQR)	9 (5-1)
<b>Family history of AA, n (%)</b>	
Siblings	56 (5.1)
Mother	47 (4.2)
Father	59 (5.3)
Grand parents	43 (3.9)
Children	32 (2.9)
At least one 1. degree family with AA	179 (12.0)

AA, Alopecia Areata; IQR, interquartile range; NRS, Numeric rating scale; SD, standard deviation

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**Table 3 – AA-specific patient reported outcomes**

Alopecia Areata

n=1494

---

**[PRO Measure for Eye Irritation]** Please rate how irritated (e.g. itching, stinging, burning, or dry) either of your eyes have

**been in the past 7 days, n(%)**

My eyes have not been irritated	828 (55.65)
My eyes have been a little irritated	436 (29.30)
My eyes have been moderately irritated	153 (10.28)
My eyes have been severely irritated	71 (4.77)

**[PRO Measure for Eyelashes]** Look at your upper and lower eyelashes on both your eyes. Please rate your eyelashes, as they look today, n(%)

I have full eyelashes on each eyelid	481 (43.61)
I have a minimal gap or minimal gaps along the eyelids	203 (18.40)
I have a large gap or large gaps along the eyelids	64 (5.80)
I have no or barely any eyelash hair	355 (32.18)

**[PRO Measure for Eyebrows]** Look at the hair in both of your eyebrows. Please rate your eyebrows, as they look today, n(%)

I have full eyebrows on each eye	412 (37.25)
I have a minimal gap(s) or a minimal amount of thinning in at least one of my eyebrows	180 (16.27)
I have a large gap(s) or a large amount of thinning in at least one of my eyebrows	114 (10.31)
I have no or barely any eyebrow hairs	400 (36.17)

**[PRO Measure for Nail Appearance]** Examine your fingernails and toenails. Please rate your fingernails and toenails, as they look today, n(%)

Nails are not at all damaged (e.g. pitted, rough, brittle, split)	522 (47.24)
At least one nail is a little damaged (e.g. pitted, rough, brittle, split)	303 (27.42)
At least one nail is moderately damaged (e.g. pitted, rough, brittle, split)	193 (17.47)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

At least one nail is very damaged (e.g. pitted, rough, brittle, split) or you have lost at least one nail 87 (7.87)

**[Scalp Hair Assessment PRO] Use mirrors to look at your entire scalp. Please rate the total area of your scalp that is missing hair right now, n(%)**

No missing hair (0% of my scalp is missing hair; I have a full head of hair) 234 (21.16)

A limited area (1-20% of my scalp is missing hair) 284 (25.68)

A moderate area (21-49% of my scalp is missing hair) 132 (11.93)

A large area (50-94% of my scalp is missing hair) 109 (9.86)

Nearly all or all (95-100% of my scalp is missing hair) 347 (31.37)

---

PRO, patient reported outcome;



## Supplementary table 1

## List of variables available from the baseline assessment interviews in the Danish Skin Cohort

Variable	Type	Choice	Details
Height	Continuous	Single	Centimetres
Weight	Continuous	Single	Kilograms
Smoking	Categorical	Single	Current daily smoker Current non-daily smoker Former smoker Never smoker
Alcohol use	Continuous	Single	Units of alcohol per week
Alcohol use	Categorical	Single	AUDIT-C for alcohol, questionnaire (multiple questions, one variable for each question)
Skin type	Categorical	Single	Fitzpatrick skin types 0-6
Leisure time activity level	Ordinal	Single	Athletic Vigorous Moderate Sedentary
Joint pain within last 7 days	Interval	Single	Numeric Rating Scale (0 to 10)
Skin pain within last 7 days	Interval	Single	Numeric Rating Scale (0 to 10)

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46	<p>Skin pruritus within last 3 days</p> <p>Trouble sleeping within last 3 days</p> <p>Age at AA onset</p> <p>Active AA in the past 12 months</p> <p>Family history of AA</p> <p>Current body surface area affected by AA at any point during the past 12 months affected by AA</p> <p>Largest body surface area affected by AA at any point during the past 12 months</p> <p>Largest body surface area affected by AA at any point during the past 12 months affected by AA at any point in your life</p> <p>Patient reported current disease severity</p> <p>Disease development/progression in the past 12 months</p>	<p>Interval</p> <p>Interval</p> <p>Continuous</p> <p>Dichotomous</p> <p>Categorical</p> <p>Interval</p> <p>Interval</p> <p>Interval</p> <p>Interval</p> <p>Categorical</p>	<p>Single</p> <p>Single</p> <p>Single</p> <p>Single</p> <p>Multiple</p> <p>Single</p> <p>Single</p> <p>Single</p> <p>Single</p> <p>Single</p>	<p>Numeric Rating Scale (0 to 10)</p> <p>Numeric Rating Scale (0 to 10)</p> <p>Age in years</p> <p>Yes / No</p> <p>Sibling Mother Father Grandparent Children</p> <p>0 to 100</p> <p>0 to 100</p> <p>0 to 100</p> <p>Numeric Rating Scale (0 to 10)</p> <p>AA has worsened a lot AA has worsened AA has remained unchanged AA has improved a little AA has improved a lot AA has gone into complete remission</p>
---	---	--	---	---

Number of disease flares in the past 12 months	Continuous	Single	A flare is defined as one or more consecutive days with significant worsening of symptoms requiring escalation of treatment or seeking additional medical advice
Time from first AA symptoms to first AA diagnosis by a physician	Continuous	Single	Time in years
Time from first AA symptoms to first AA diagnosis by a dermatologist	Continuous	Single	Time in years
Seasonal changes in severity	Categorical	Multiple	Worsens during spring Worsens during summer Worsens during fall Worsens during winter No seasonal variation
WPAI			Work productivity and activity index Multiple variables (one for each question)
EQ-5D-5L			EuroQoL 5 Dimensions 5 Levels Multiple variables (one for each question)
DLQI			Dermatology Life Quality Index Multiple variables (one for each question)
MFI-20			Multidimensional Fatigue Inventory Multiple variables (one for each question)
AASIS			Alopecia Areata Symptom Impact Scale Multiple variables (one for each question)
PRO Measure for Eye Irritation	Ordinal	Single	Please rate how irritated (e.g. itching, stinging, burning, or dry) either of your eyes have been in the past 7 days.

			<p>My eyes have not been irritated</p> <p>My eyes have been a little irritated</p> <p>My eyes have been moderately irritated</p> <p>My eyes have been severely irritated</p>
PRO Measure for Eyebrows	Ordinal	Single	<p>Look at the hair in both of your eyebrows. Please rate your eyebrows, as they look today. This question asks about gap(s) in your eyebrows or thinning in your eyebrows. If you have gap(s) in your eyebrows and thinning in your eyebrows, please choose your answer based on the type of hair loss that bothers you the most.</p> <p>I have full eyebrows on each eye</p> <p>I have a minimal gap(s) or a minimal amount of thinning in at least one of my eyebrows</p> <p>I have a large gap(s) or a large amount of thinning in at least one of my eyebrows</p> <p>I have no or barely any eyebrow hairs</p>
PRO Measure for Eyelashes	Ordinal	Single	<p>Look at your upper and lower eyelashes on both your eyes. Please rate your eyelashes, as they look today.</p> <p>I have full eyelashes on each eyelid</p> <p>I have a minimal gap or minimal gaps along the eyelids</p> <p>I have a large gap or large gaps along the eyelids</p> <p>I have no or barely any eyelash hair</p>
PRO Measure for Nail Appearance	Ordinal	Single	<p>Examine your fingernails and toenails. Please rate your fingernails and toenails, as they look today.</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

			<p>Nails are not at all damaged (e.g. pitted, rough, brittle, split)</p> <p>At least one nail is a little damaged (e.g. pitted, rough, brittle, split)</p> <p>At least one nail is moderately damaged (e.g. pitted, rough, brittle, split)</p> <p>At least one nail is very damaged (e.g. pitted, rough, brittle, split) or you have lost at least one nail</p>
Scalp Hair Assessment PRO	Ordinal	Single	<p>Use mirrors to look at your entire scalp.</p> <p>Please rate the total area of your scalp that is missing hair right now.</p> <p>Areas of vellus hair (peach fuzz or baby hair) should also be considered as missing hair.</p> <p>No missing hair (0% of my scalp is missing hair; I have a full head of hair)</p> <p>A limited area (1-20% of my scalp is missing hair)</p> <p>A moderate area (21-49% of my scalp is missing hair)</p> <p>A large area (50-94% of my scalp is missing hair)</p> <p>Nearly all or all (95-100% of my scalp is missing hair)</p>

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7
Bias	9	Describe any efforts to address potential sources of bias	NA
Study size	10	Explain how the study size was arrived at	7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Table
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6-7
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	NA
		(d) If applicable, describe analytical methods taking account of sampling strategy	Na
		(e) Describe any sensitivity analyses	Na
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	7
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8-11
		(b) Indicate number of participants with missing data for each variable of interest	
Outcome data	15*	Report numbers of outcome events or summary measures	8-11
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	8-11

		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	11-12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12
Generalisability	21	Discuss the generalisability (external validity) of the study results	12
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	None

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).